idarubicin has been researched along with daunorubicin in 424 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 126 (29.72) | 18.7374 |
| 1990's | 123 (29.01) | 18.2507 |
| 2000's | 86 (20.28) | 29.6817 |
| 2010's | 75 (17.69) | 24.3611 |
| 2020's | 14 (3.30) | 2.80 |
| Authors | Studies |
|---|---|
| Heijn, M; Hooijberg, JH; Lankelma, J; Scheffer, GL; Szabó, G; Westerhoff, HV | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Clardy, J; Derbyshire, ER; Mota, MM; Prudêncio, M | 1 |
| Ebenstein, Y; Frenkel, M; Fridman, M; Goldstein, EB; Grunwald, A; Mittelman, L; Shaul, P; Tsarfaty, I | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Casazza, AM; Di Marco, A; Formelli, F; Mariani, A; Pollini, C | 1 |
| Huguet, F; Hurteloup, P; Michallet, M; Reiffers, J; Stoppa, AM | 1 |
| Belloc, F; Bernard, P; Boisseau, MR; Dumain, P; Lacombe, F; Lopez, F; Reifers, J | 1 |
| Di Mario, A; Etuk, B; Leone, G; Pagano, L; Salutari, P; Sica, S | 1 |
| Ames, MM; Spreafico, F | 1 |
| Berman, E | 2 |
| Abgrall, JF; Desablens, B; Dufour, P; Guyotat, D; Harousseau, JL; Herve, P; Ifrah, N; Milpied, N; Pignon, B; Solary, E | 1 |
| Resegotti, L | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
| Ames, MM; Kuffel, MJ; Reid, JM | 1 |
| Berman, E; McBride, M | 1 |
| Banks, PL; Bartolucci, AA; Flaum, MA; Gerber, MC; Omura, GA; Velez-Garcia, E; Vogler, WR; Weiner, RS | 1 |
| Camaggi, CM; Carisi, P; Pannuti, F; Strocchi, E | 1 |
| Camaggi, CM; Carisi, P; Efthymiopoulos, C; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E; Strolin-Benedetti, M; Tononi, A | 1 |
| Arlin, ZA; Banks, PL; Case, DC; Enck, RE; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Baum, E; Feig, SA; Harris, RE; Holcenberg, JS; Kaizer, H; Krailo, MD; Pendergrass, TW; Saunders, EF; Steinherz, L; Warkentin, PL | 1 |
| Wiernik, PH | 1 |
| Ardia, A; Di Pietro, N; Di Raimondo, F; Falconi, E; Ganzina, F; Geraci, E; Ladogana, S; Latagliata, R; Mandelli, F; Petti, MC | 1 |
| Hanrahan, A; Lobo, PJ; Powles, RL; Reynold, DK | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, S; Kolitz, J; McKenzie, S; Santorsa, J | 1 |
| Cairo, MS; Sender, L; Toy, C; van de Ven, C | 1 |
| Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J | 1 |
| Ames, MM; Hammond, GD; Krailo, MD; Pendergrass, TW; Reid, JM | 1 |
| Barbui, T; Biondi, A; Catapano, C; D'Incalci, M; Giudici, G; Limonta, M; Masera, G; Specchia, G | 1 |
| D'Incalci, M; Erranti, D; Freshi, A; Tirelli, U; Zanette, L; Zucchetti, M | 1 |
| Capalbo, MI; Stipani, I; Zara, V | 1 |
| Haanen, C; Minderman, H; Speth, PA | 1 |
| Omura, G; Raney, M; Velez-Garcia, E; Vogler, WR | 1 |
| Arlin, ZA | 1 |
| Andreeff, M; Berman, E; Clarkson, BD; Gabrilove, J; Gee, TS; Gulati, S; Kempin, SJ; Raymond, V; Wiernik, PH; Young, CW | 1 |
| Bastholt, L; Dalmark, M; Ebbehøj, E; Elbaek, K; Jakobsen, A; Juul, P; Rasmussen, SN; Steiness, E | 1 |
| Eksborg, S; Nilsson, B | 1 |
| Ellis, AL; Gewirtz, DA; Randolph, JK; Woods, KE | 1 |
| Grankvist, K; Henriksson, R; Stendahl, U | 1 |
| de Graaf, SS; Evans, WE; Riley-Stewart, CA | 1 |
| Benfield, GF; Cullen, MH; Smith, SR; Woodroffe, CM | 1 |
| McKenzie, IF; Pietersz, GA; Smyth, MJ | 3 |
| Chen, ZM; Colombo, T; Conforti, L; Fiedorowicz, RJ; Grazia Donelli, M; Latini, R; Marchi, S; Paolini, A; Riva, E; Zuanetti, G | 1 |
| Mandelli, F; Petti, MC | 1 |
| Arlin, ZA; Case, DC; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW | 1 |
| Raymond, V; Young, CW | 1 |
| Clagett-Carr, K; Leyland-Jones, B; Russo, M; Sarosy, G; Weiss, RB | 1 |
| de Vries, EG; Le, TK; Meijer, C; Mulder, NH; Timmer-Bosscha, H; Zijlstra, JG | 1 |
| Banham, SW; Cummings, J; Kaye, SB; Milroy, R | 2 |
| Brandi, M; De Lena, M; Logroscino, A; Lorusso, V; Maiello, E; Paradiso, A | 1 |
| Bozzi, D; Brandi, M; Calabrese, P; De Lena, M; Romito, S | 1 |
| Christoffersen, PS; Hermansen, K; Rasmussen, KK | 1 |
| Cox, G; Gillies, H; Harper, P; Johnson, S; Liang, R; Parapia, L; Rogers, H | 1 |
| Blackledge, GR; Cullen, MH; Priestman, TJ; Stuart, NS; Tyrrell, CJ | 1 |
| Capnist, G; Chisesi, T; de Dominicis, E; Dini, E | 1 |
| Kolarić, K; Mechl, Z; Potrebica, V; Sopkova, B; Vukas, D | 1 |
| Alpert, BS; de Graaf, SS; Dow, LW; Evans, WE; Murphy, SB; Pui, CH; Rodman, JH | 1 |
| Falkson, G; Iturralde, MP; Vorobiof, DA | 1 |
| Airiau, J; Bégué, JM; Guillouzo, A; Kernaleguen, D; Le Bot, MA; Ratanasavanh, D; Riché, C; Robert, J | 1 |
| Robert, J | 1 |
| Arcamone, F; Lazzati, M; Vicario, GP; Zini, G | 1 |
| Angelelli, B; Camaggi, CM; Comparsi, R; Pacciarini, MA; Pannuti, F; Strocchi, E | 1 |
| Copeland, LJ; Edwards, CL; Gershenson, DM; Kavanagh, JJ; Saul, PB | 1 |
| Beer, M; Crespeigne, N; Dodion, P; Finet, C; Kenis, Y; Nicaise, C; Rozencweig, M | 1 |
| Di Lauro, L; Di Pietro, N; Ganzina, F; Lazzaro, B; Lopez, M; Papaldo, P | 2 |
| Annaloro, C; Lambertenghi-Deliliers, G; Pacciarini, MA; Pogliani, E; Polli, EE | 1 |
| Bodey, GP; Burgess, M; Feun, LG; Kavanagh, J; Loo, TL; Lu, K; Savaraj, N | 1 |
| Dougherty, JB; Hakes, TB; Raymond, V | 1 |
| Coccia-Portugal, MA; Dreyer, R; Falkson, G; Terblanche, AP; Vorobiof, DA | 1 |
| Cummings, J; Morrison, JG; Willmott, N | 1 |
| Battista, R; D'Emilio, A; Dini, E; Pacciarini, MA; Vespignani, M | 1 |
| Haanen, C; Linssen, PC; Speth, PA; van de Loo, FA; Wessels, HM | 1 |
| Amoroso, D; Conte, PF; Lionetto, R; Pronzato, P; Rosso, R; Sertoli, MR | 1 |
| Löwenberg, B; Schölzel, C; van Putten, W | 1 |
| Martoni, A; Pacciarini, MA; Pannuti, F; Piana, E | 1 |
| Di Lauro, L; Lopez, M; Papaldo, P | 1 |
| Blum, RH; Green, MD; Hochster, HS; Muggia, FM; Speyer, JL; Wernz, JC | 1 |
| Bonadonna, G; Bonfante, V; Brambilla, C; Crippa, F; Ferrari, L; Rossi, A; Valagussa, P; Villani, F | 1 |
| Gillies, HC; Harper, PG; Herriott, D; Liang, R; Ohashi, K; Rogers, HJ | 1 |
| Bacha, DM; Dantis, E; Hancock, C; Luks, E; Meyers, P; Mondora, A; Steinherz, L; Steinherz, P; Tan, CT; Winick, N | 1 |
| Bastholt, L; Dalmark, M | 1 |
| Hakes, TB; Raymond, V | 1 |
| Howell, A; Lucas, SB; Margison, JM; Smith, DB; Wilkinson, PM | 1 |
| Kolarić, K; Mechl, Z; Potrebica, V; Sopkova, B | 1 |
| Cheng, EW; Magill, GB; Mittelman, A; Raymond, V; Sordillo, PB; Sternberg, CN; Young, CW | 1 |
| Abramson, HN; Banning, JW; Corbett, TH; Wormser, HC; Wu, JD | 1 |
| Fujita, H; Hattori, M; Kimura, K; Ogawa, M; Shimoyama, T; Taguchi, T; Wakui, A | 1 |
| Capranico, G; Dasdia, T; Riva, A; Tinelli, S; Zunino, F | 1 |
| Bruzzone, M; Chiara, S; Conte, PF; Falcone, A; Graziani, G; Rosso, R | 1 |
| Berens, ME; Modest, EJ; Saito, T; Welander, CE | 1 |
| Howell, A; Smith, DB | 1 |
| Bagnulo, S; Canino, R; Carli, M; Colella, R; Comelli, A; De Bernardi, B; Grazia, G; Madon, E; Paolucci, G; Sainati, L | 1 |
| Fülle, HH; Hellriegel, KP | 2 |
| Carcassonne, Y; Dufour, P; Harousseau, JL; Hayat, M; Hurteloup, P; Jaubert, J; Le Prise, PY; Monconduit, M; Reiffers, J; Rigal-Huguet, F | 1 |
| Annaloro, C; Cortelezzi, A; Ganzina, F; Lambertenghi-Deliliers, G; Maiolo, AT; Pogliani, E; Polli, EE | 1 |
| Libretti, A; Moro, E; Pacciarini, MA; Piazza, E; Tamassia, V; Vago, G | 1 |
| Johnson, E; Parapia, LA | 1 |
| Chesterman, CN; Griffiths, JD; Harris, MG; Herrmann, RP; Lowenthal, RM; Manoharan, A; Rooney, KF; Rozenberg, MC; Salem, HH; Wolf, MM | 1 |
| Casper, ES; Currie, VE; Hakes, TB; Kaufman, RJ; Raymond, V | 1 |
| Boaziz, C; Caillou, B; Parmentier, C; Schlumberger, M | 1 |
| Harousseau, JL; Huet, S; Hurteloup, P; Pris, J; Reiffers, J; Rigal-Huguet, F; Robert, J; Tamassia, V | 1 |
| Carella, AM; Cerri, R; Congiu, A; Damasio, E; Gaozza, E; Giordano, D; Martinengo, M; Nati, S; Risso, M; Santini, G | 1 |
| Dodion, P; Kenis, Y; Mattelaer, MA; Rombaut, W; Rozencweig, M; Sanders, C; Stryckmans, P | 1 |
| Di Pietro, N; Ganzina, F; Pacciarini, MA | 1 |
| Broggini, M; Dolfini, E; Donelli, MG; Paolini, A; Sommacampagna, B | 1 |
| Ganzina, F; Hurteloup, P | 1 |
| Meyer, D; Nagel, GA; Schuff-Werner, P; Wander, HE | 1 |
| Kimura, Y; Matsumoto, T; Ohsaki, M; Suzuki, M; Terashima, S | 1 |
| Ahmed, T; Budman, D; Scher, HI; Sordillo, P; Watson, RC; Yagoda, A | 1 |
| Arlin, ZA; Baratz, R; Budman, D; Daghestani, AN; Gee, TS; Kempin, SJ; Leyland-Jones, B; Mertelsmann, R; Schulman, P; Williams, L | 1 |
| Carella, AM; Cerri, R; Congiu, A; Damasio, E; Giordano, D; Martinengo, M; Nati, S; Risso, M; Rossi, E; Santini, G | 1 |
| Eridani, S; Pearson, TC; Singh, AK; Slater, NG | 1 |
| Daghestani, AN; Dougherty, JB; Hakes, TB; Raymond, V; Weiselberg, L | 1 |
| Carella, AM; Cerri, R; Congiu, A; Frassoni, F; Giordano, D; Marmont, A; Martinengo, M; Nati, S; Risso, M; Santini, G | 1 |
| Martoni, A; Pacciarini, MA; Pannuti, F | 2 |
| Burke, MT; Casper, ES; Cibas, IR; Fiore, JJ; Gralla, RJ; Heelan, RT; Kelsen, DP; Kris, MG | 1 |
| Arcamone, F | 2 |
| Kavanagh, JJ; Krakoff, IH; Savaraj, N; Yeung, KY | 1 |
| Cavalli, F; Fopp, M; Sessa, C; Tschopp, L | 1 |
| Bayle, C; Berger, R; Carde, P; Finaud, M; Hayat, M; Hurteloup, P; Morardet, N; Parmentier, C; Schlumberger, M | 1 |
| Ogawa, M | 1 |
| Kimura, Y; Matsumoto, T; Suzuki, M; Terashima, S | 1 |
| Alberto, P; Cavalli, F; Joss, RA; Obrecht, JP; Siegenthaler, P; VanHelvoirt, A | 1 |
| Babudri, N; Monti-Bragadin, C; Pani, B; Tamaro, M; Zunino, F | 1 |
| Rogers, KE; Tökés, ZA | 1 |
| Alexander, J; Khanna, I; Lednicer, D; Mitscher, LA; Veysoglu, T; Wielogorski, Z; Wolgemuth, RL | 1 |
| Bachmann, E; Beilstein, AK; Zbinden, G | 1 |
| Dawson, KM | 1 |
| Bellotti, V; Jannuzzo, MG; Moro, E; Stegnjaich, S; Valzelli, G | 1 |
| Bottiroli, G; Croce, AC; Dasdia, T; Prosperi, E; Supino, R | 1 |
| Coonley, CJ; Straus, DJ; Warrell, RP; Young, CW | 1 |
| Baratz, R; Berman, E; Casper, ES; Gralla, RJ; Howard, J; Leyland-Jones, B; Williams, L; Wittes, RE; Young, CW | 1 |
| Lambertenghi-Deliliers, G; Maiolo, AT; Pacciarini, MA; Pogliani, E; Polli, EE | 1 |
| Ahmed, T; Arena, F; Cheng, E; Faye, L; Harper, HD; Kemeny, NE; Sordillo, P | 1 |
| Annaloro, C; Baldini, L; Lambertenghi-Deliliers, G; Maiolo, AT; Pogliani, E; Polli, E | 1 |
| Broggini, M; Colombo, T; Donelli, MG; Italia, C; Marmonti, L | 1 |
| Arcamone, F; Menozzi, M; Valentini, L; Vannini, E | 1 |
| Bonadonna, G; Bonfante, V; Ferrari, L; Villani, F | 1 |
| Cheng, E; Einzig, A; Kelsen, D; Magill, G; Raymond, V; Sordillo, P | 1 |
| Cavalli, F; Kaplan, S; Pacciarini, MA; Sessa, C; Tamassia, V; Willems, Y | 1 |
| Carde, P; Chahine, G; Hayat, M; Hurteloup, P; Kamioner, D; Parmentier, C; Pico, JO; Schlumberger, M | 1 |
| Di Marco, A; Lambertenghi-Deliliers, G; Nava, M; Pozzoli, EF; Praga, C; Soligo, DA; Zanon, PL | 1 |
| Casazza, AM; Di Marco, A; Giuliani, F; Pratesi, G | 1 |
| Bogliolo, G; D'Amore, F; Ghio, R; Massa, G; Muzzulini, C; Pannacciulli, I | 1 |
| Cavalli, F; Kaplan, S; Martini, A; Togni, P; Varini, M | 1 |
| Arcamone, F; Cassinelli, G; Di Marco, A | 1 |
| Konoshita, M; Naganawa, H; Takahashi, Y; Takeuchi, T; Tatsuta, K; Umezawa, H | 1 |
| Cornblatt, B; Doyle, LA; Ross, DD; Tong, Y; Yang, W | 1 |
| Curtis, JE; McCulloch, EA; Minden, MD; Minkin, S | 1 |
| Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F | 1 |
| Dekker, H; Lankelma, J; Mülder, HS; Pinedo, HM | 1 |
| Barron, JT; Ghalie, R; Kaizer, H; Kakavas, PW; Parrillo, JE | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| den Boer, ML; Huismans, DR; Klumper, E; Loonen, AH; Pieters, R; Veerman, AJ | 1 |
| Ames, MM; Kuffel, MJ | 1 |
| Butelli, E; Capranico, G; Zunino, F | 1 |
| Cenacchi, A; Gamberi, B; Manfroi, S; Ottaviani, E; Tosi, P; Tura, S; Visani, G | 1 |
| Caron, PC; Finn, RD; Jurcic, JG; Larson, SM; Maslak, P; Miller, WH; Scheinberg, DA; Warrell, RP; Yao, TJ | 1 |
| Cianfriglia, M; Eisterer, W; Gotwald, M; Hilbe, W; Hofmann, J; Ludescher, C; Thaler, J; Zabernigg, A | 1 |
| Götzl, M; Gsur, A; Kyrle, PA; Lechner, K; Pirker, R; Zöchbauer, S | 1 |
| al-Sabah, A; Baines, P; Burnett, A; Hoy, T; Limaye, M; Padua, RA; Whittaker, J | 1 |
| Conley, NS; Doughney, KB; Durkin, WJ; Favis, GR; Siddiqui, T; Smith, AE; Weiss, R | 1 |
| Boiocchi, M; Gigante, M; Simone, F; Toffoli, G | 1 |
| Cedrych, I; Hołowiecka, B; Hołowiecki, J; Kachel, L; Krawczyk, M; Krzemień, S; Rudzka, E; Wacławik, A; Wojciechowska, M; Wojnar, J | 1 |
| Fukushima, T; Kawai, Y; Nakamura, T; Ueda, T; Urasaki, Y; Yoshida, A | 1 |
| Belloc, F; Boiron, JM; Cony-Makhoul, P; Dubosc-Marchenay, N; Dumain, P; Fabères, C; Lacombe, F; Marit, G; Montastruc, M; Puntous, M | 1 |
| Biersack, H; Brieden, T; Gieseler, F; Manderscheid, J; Nüssler, V | 1 |
| Baccarani, M; Damiani, D; Lauria, F; Michelutti, A; Michieli, M; Pipan, C; Raspadori, D | 1 |
| Baccarani, M; Cerno, M; Damiani, D; Melli, C; Michelutti, A; Michieli, M | 1 |
| Boezeman, J; de Witte, T; Haanen, C; Linssen, P; Minderman, H; van der Lely, N; Wessels, J | 1 |
| Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
| Belloc, F; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Lopez, F; Mahon, FX; Marit, G; Montastruc, M; Puntous, M | 1 |
| Eardley, AM; Heller, G; Warrell, RP | 1 |
| Kaletin, GI; Pirogova, NA; Volkova, MA | 1 |
| Perilov, AA; Poddubnaia, IV | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohhashi, Y; Yamada, K | 1 |
| Almqvist, A; Hallman, H; Honkanen, T; Järvenpää, E; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Ruutu, T | 1 |
| Fukushima, T; Nakamura, T; Uchida, M; Ueda, T | 1 |
| Haanen, C; Malmberg, M; Minderman, H; Rustum, YM; Slocum, HK | 1 |
| Baccarani, M; Damiani, D; Fanin, R; Michelutti, A; Michieli, M; Russo, D | 1 |
| Falk, RE; Fuerst, MM; Giles, FJ; Kusuanco, DA; Lawrence, GN; Lim, SW; Look, RM | 1 |
| Bamberger, U; Esteban, M; Heckel, A; Kasimir-Bauer, S; Müller, MR; Scheulen, ME; Schröder, J; Seeber, S | 1 |
| Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M | 2 |
| Attal, M; Berthaud, P; Broustet, A; Danel, P; Fabères, C; Gastaut, JA; Hollard, D; Huguet, F; Hurteloup, P; Lepeu, G; Maraninchi, D; Marit, G; Mercier, M; Michallet, M; Molina, L; Pris, J; Reiffers, J; Stoppa, AM; Tellier, Z | 1 |
| Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G | 1 |
| Dubru, F; Fiallo, M; Garnier-Suillerot, A; Hesschenbrouck, J; Mankhetkorn, S | 1 |
| Garnier-Suillerot, A; Jollès, B; Laigle, A; Priebe, W | 1 |
| Gieseler, F; Glasmacher, A; Kämpfe, D; Kunze, J; Nuessler, V; Valsamas, S; Wandt, H; Wilms, K | 2 |
| Barbui, T; Bassan, R; Lerede, T; Rambaldi, A | 1 |
| Boiocchi, M; Corona, G; De Angeli, S; Gigante, M; Simone, F; Toffoli, G | 1 |
| Kearns, P; Majumdar, G; Partridge, F; Richardson, W; Wilcox, R | 1 |
| Audhuy, B; Baranger, L; Berthaud, P; Berthou, C; Briere, J; Cahn, JY; Caillot, D; Casassus, P; Desablens, B; Francois, S; Guyotat, D; Harousseau, JL; Herve, P; Hurteloup, P; Leprise, PY; Linassier, C; Lioure, B; Pignon, B; Polin, V; Sadoun, A; Vilque, JP; Witz, F | 1 |
| Paul, C; Prenkert, M; Tidefelt, U | 1 |
| Cattan, AR; Maung, ZT | 1 |
| Belotti, D; Corneo, G; Maffè, PF; Pogliani, EM; Rivolta, GF | 1 |
| Ames, MM; Bleyer, WA; Feig, SA; Gerber, M; Harris, RE; Leonard, M; Pendergrass, TW; Reid, JM; Sather, HN; Steinherz, L; Trigg, M; Warkentin, P | 1 |
| Clark, M; Gieseler, F; Glasmacher, A; Kämpfe, D; Kunze, J; Valsamas, S; Zernak, C | 1 |
| Davey, MW; Davey, RA; Hargrave, RM | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohashi, Y; Yamada, K | 1 |
| Abbadessa, V; Cajozzo, A; Gancitano, RA; Musso, M; Perricone, R; Porretto, F; Tolomeo, M | 1 |
| Baguley, BC; Davey, MW; Davey, RA; Hargrave, RM; Harvie, RM; Su, GM | 1 |
| Abenhardt, W; Diem, H; Gieseler, F; Gullis, E; Kolb, HJ; Langenmayer, I; Nüssler, V; Pelka-Fleischer, R; Schmitt, R; Wilmanns, W; Wohlrab, A; Zwierzina, H | 1 |
| Baltes-Engler, S; Dederichs, B; Diehl, V; Engelhard, M; Engert, A; Küpper, F; Lathan, B; Reiser, M; Scheulen, ME; Schnell, R; Tesch, H; Wilhelm, M; Winterhalter, B; Wörmann, B | 1 |
| Belloc, F; Bernard, P; Besnard, S; Boisseau, MR; Dumain, P; Lacombe, F; Reiffers, J; Vial, JP | 1 |
| Linke, R; Looby, M; Weiss, M | 1 |
| Björkholm, M; Eksborg, S; Fagerlund, E; Hast, R | 1 |
| Ohnishi, K; Ohno, R; Shinjyo, K; Takeshita, A; Tobita, T; Yanagi, M | 1 |
| Nagasawa, K; Ohnishi, N; Yokoyama, T | 1 |
| Blaschke, G; Boos, J; Haberland, S; Hempel, G; Möhling, N; Schulze-Westhoff, P | 1 |
| Abgrall, JF; Audhuy, B; Briere, J; Cahn, JY; Caillot, D; Casassus, P; Delain, M; Desablens, B; Francois, S; Guilhot, F; Guyotat, D; Harousseau, JL; Herve, P; Hurteloup, P; Lamy, T; Lioure, B; Milpied, N; Pignon, B; Tellier, Z; Witz, F | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Bartolucci, A; Berman, E; Vélez-Gárcia, E; Vogler, R; Whaley, FS; Wiernik, P | 1 |
| Brieden, T; Gieseler, F; Kunze, J; Nüssler, V; Valsamas, S | 1 |
| Fiallo, M; Gallois, L; Garnier-Suillerot, A | 1 |
| Garnier-Suillerot, A; Mankhetkorn, S | 1 |
| Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF | 1 |
| Bondi, F; Crescimanno, A; Mariani, G; Musso, M; Polizzi, V; Porretto, F; Scalone, R; Tolomeo, M | 1 |
| Fukushima, T; Imamura, S; Inai, K; Inoue, H; Kishi, S; Nakamura, T; Nakayama, T; Takemura, H; Ueda, T; Urasaki, Y; Yamauchi, T | 1 |
| Itoh, R; Mizuno, T; Morita, K; Suzuki, H; Tanaka, I | 1 |
| Biondi, A; Coppi, MR; Liso, V; Mestice, A; Mininni, D; Palumbo, G; Pogliani, EM; Rossi, V; Specchia, G; Teruzzi, E | 1 |
| Bolard, J; Heywang, C; Masson, CM; Saint-Pierre Chazalet, M | 1 |
| Bernasconi, C; Castagnola, C; Corso, A; Dabusti, M; Lazzarino, M; Lunghi, M; Tajana, M; Zappasodi, P | 1 |
| Akan, H; Arat, M; Arslan, O; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Fukushima, T; Imamura, S; Misaki, H; Ueda, T; Urasaki, Y; Yamashita, T; Yamauchi, T; Yoshio, N | 1 |
| Aguado, MJ; Arrieta, R; Bustos, JG; Canales, MA; Hernández-García, C; Hernández-Navarro, F | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Mollee, PN; Rodwell, R; Taylor, D; Taylor, KM; Williams, B | 1 |
| Barbui, T; Bassan, R; Chiodini, B | 2 |
| Barbara, C; Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A; Fogli, S; Innocenti, F | 1 |
| Bloem, AC; Lokhorst, HM; Roovers, DJ; van Vliet, M | 1 |
| Hofmann, S; Kuhlmann, O; Weiss, M | 1 |
| Garnier-Suillerot, A; Mankhetkorn, S; Teodori, E | 1 |
| Fiallo, MM; Garnier-Suillerot, A; Kozlowski, H; Matzanke, B | 1 |
| Fumihara, T; Nagasawa, K; Ohnishi, N; Yokoyama, T | 1 |
| Boezeman, J; de Witte, TM; Minderman, H; Pennings, AH; Raymakers, RA; Smeets, ME; Vierwinden, G | 1 |
| de Witte, T; Pennings, AH; Raymakers, RA; Smeets, ME; Vierwinden, G; Wessels, H | 1 |
| Filipits, M; Geissler, K; Jäger, U; Lechner, K; Pirker, R; Pohl, G; Scheper, RJ; Stranzl, T; Suchomel, RW | 1 |
| de Waal, E; Lankelma, J; Westerhoff, HV; Wielinga, PR | 1 |
| Mandelli, F; Montefusco, E | 1 |
| Lankelma, J; Westerhoff, HV; Wielinga, PR | 1 |
| Kasimir-Bauer, S; Scheulen, ME; Schröder, JK; Seeber, S | 1 |
| Clark, M; Gieseler, F; Puschmann, M; Stiebeling, K; Valsamas, S | 1 |
| Bascans, E; Belaud-Rotureau, MA; Belloc, F; Braz-Pereira, E; Durrieu, F; Lacombe, F; Lavignolle, V | 1 |
| Fujii, S; Fukushi, Y; Futagami, M; Higuchi, T; Saito, Y; Sakamoto, T; Sato, S; Takami, H; Yokoyama, Y | 1 |
| Boros, B; Egyed, M; Földi, J; Páldi-Haris, P; Rumi, G | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Agape, P; Belaud-Rotureau, MA; Belloc, F; Durrieu, F; Fitoussi, O; Labroille, G; Lacombe, F; Marit, G; Reiffers, J | 1 |
| Jensen, PB; Langer, SW; Sehested, M | 1 |
| Huismans, DR; Pieters, R; Schuurhuis, GJ; Styczynski, J; Veerman, AJ; Wysocki, M | 1 |
| Aivado, M; Aul, C; Gattermann, N; Germing, U; Haas, R; Kobbe, G; Rieth, C; Rong, A | 1 |
| Bravo, E; Martínez-Lozano, C; Pérez-Ruiz, T; Sanz, A | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Boos, J; Creutzig, U; Feldges, A; Gadner, H; Hermann, J; Kühl, J; Niemeyer, CM; Ritter, J; Sawatzki, DB; Schwabe, D; Selle, B; Zimmermann, M | 1 |
| de Witte, T; Linssen, P; Masereeuw, R; Muus, P; Raymakers, R; Smeets, M; Vierwinden, G | 1 |
| Cabrera, ME; Ducach, G; Etcheverry, R; Puga, BL; Toledo, H; Undurraga, MS; Vacarezza, R | 1 |
| Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Berthold, F; Creutzig, U; Gadner, H; Havers, W; Henze, G; Hermann, J; Jürgens, H; Kabisch, H; Kluba, U; Niggli, F; Reinhardt, D; Reiter, A; Ritter, J; Zimmermann, M | 1 |
| Bernasconi, P; Boni, M; Castoldi, GL; Ciolli, S; Clavio, M; Cox, MC; Cuneo, A; Del Poeta, G; Dini, D; Falzetti, D; Fanin, R; Gobbi, M; Isidori, A; Leoni, F; Liso, V; Malagola, M; Mandelli, F; Martinelli, G; Mecucci, C; Petti, MC; Piccaluga, PP; Rondelli, R; Russo, D; Sessarego, M; Specchia, G; Testoni, N; Torelli, G; Tura, S; Visani, G | 1 |
| Goh, YT; Koh, LP; Tan, P; Teoh, G | 1 |
| Drechsel, H; Fiallo, M; Garnier-Suillerot, A; Matzanke, BF; Schünemann, V | 1 |
| Fukushima, T; Goto, N; Kuraishi, Y; Ogawa, M; Ohno, R; Okabe, KI; Ueda, T; Urabe, A; Yamashita, T | 1 |
| Heller, G | 1 |
| Anagnostopoulos, N; Androutsos, G; Galanopoulos, A; Kalmantis, T; Meletis, J; Paterakis, G; Rombos, Y; Sagriotis, A; Symeonidis, A; Tiniakou, M; Tsimberidou, AM; Yataganas, X; Zoumbos, N | 1 |
| Kang, W; Weiss, M | 2 |
| Gatto, B; Moro, S; Palumbo, M; Sissi, C; Zagotto, G | 1 |
| Bruggers, CS; Carroll, WL; Liu, T; Moos, PJ; Perkins, SL; Raetz, E; Smith, F | 1 |
| Schlattner, U; Tokarska-Schlattner, M; Wallimann, T | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
| Lotfi, K; Peterson, C; Zackrisson, AL | 1 |
| Bargoni, A; Cavalli, R; Fundarò, A; Gasco, MR; Vighetto, D; Zara, GP | 1 |
| Austin, CA; Errington, F; Tilby, MJ; Willmore, E | 1 |
| Balcerska, A; Balwierz, W; Chybicka, A; Debski, R; Kowalczyk, J; Kurylak, A; Matysiak, M; Rokicka-Milewska, R; Sońta-Jakimczyk, D; Styczyński, J; Wachowiak, J; Wysocki, M | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Bogdanovic, A; Colovic, M; Colovic, N; Jankovic, G; Miljic, P | 1 |
| Lockwood, L; Marshall, GM; O'Brien, TA; Oswald, CM; Rice, M; Russell, SJ; Shaw, PJ; Teague, L; Tiedemann, K; Vowels, MR | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Estey, EH; Thall, PF | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Auvrignon, A; Bastard, C; Blaise, D; Castaigne, S; Dastugue, N; Delaunay, J; Dombret, H; Fenaux, P; Fière, D; Harousseau, JL; Lamy, T; Leblanc, T; Leverger, G; Mugneret, F; Pigneux, A; Reiffers, J; Rigal-Huguet, F; Van den Akker, J; Vey, N; Witz, F | 1 |
| Dragojew, S; Jóźwiak, Z; Kania, K | 1 |
| Creutzig, U; Griesinger, F; Hählen, K; Harbott, J; Huismans, DR; Kaspers, GJ; Meshinchi, S; Munske, L; Pieters, R; Podleschny, M; Radich, JP; Reinhardt, D; Veerman, AJ; Zimmermann, M; Zwaan, CM | 1 |
| Higa, T; Imai, A; Imamura, M; Kasai, M; Kiyama, Y; Kobayashi, N; Kondo, Y; Miyokawa, N; Ogasawara, M; Ogawa, T; Sato, K; Tanaka, J; Toubai, T | 1 |
| Bernabei, P; Biscardi, M; Caporale, R; Ciolli, S; Grossi, A; Leoni, F; Pagliai, G; Santini, V | 1 |
| McHowat, J; Sarvazyan, N; Swift, L | 1 |
| Boiron, JM; Boucheix, C; Bourhis, JH; Dhedin, N; Fière, D; Gallo, JH; Lhéritier, V; Reman, O; Rubio, MT; Thomas, X; Vernant, JP | 1 |
| Alonzo, TA; Aplenc, R; Arndt, C; Barnard, D; Dinndorf, P; Feig, S; Feusner, J; Gerbing, R; Lange, BJ; Seibel, N; Smith, FO; Weiman, M | 1 |
| Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S | 1 |
| Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G | 1 |
| Franco, A; Lehmann, M; Reguly, ML; Rodrigues de Andrade, HH; Vilar, Kde S | 1 |
| Aita, P; Basso, B; Boiocchi, M; Corona, G; Ruolo, G; Rupolo, M; Sorio, R; Toffoli, G | 1 |
| Boiron, JM; Boulat, O; Espinouse, D; Fiere, D; Garban, F; Gardin, C; Huguet, F; Lhéritier, V; Reman, O; Sutton, L; Thomas, X; Turlure, P | 1 |
| Benderra, Z; Chaoui, D; Faussat, AM; Legrand, O; Marie, JP; Perrot, JY; Sayada, L | 1 |
| Miura, T; Muraoka, S | 1 |
| Seiter, K | 1 |
| Asou, N; Emi, N; Honda, S; Kishimoto, Y; Matsuda, S; Matsushima, T; Mitani, K; Miyawaki, S; Miyazaki, Y; Ogawa, Y; Ohno, R; Ohtake, S; Sakamaki, H; Takahashi, M; Yagasaki, F | 1 |
| Giessler, C; Kang, W; Weiss, M | 1 |
| Barbara, C; Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A; Fioravanti, A; Orlandi, P | 1 |
| Corona, G; Crivellari, D; Lestuzzi, C; Lombardi, D; Lucenti, A; Magri, MD; Massacesi, C; Sorio, R; Talamini, R; Toffoli, G; Veronesi, A | 1 |
| Belloc, F; Lacombe, F; Pigneux, A; Praloran, V; Tabrizi, R; Vial, JP | 1 |
| Creutzig, U; Dworzak, M; Graf, N; Hermann, J; Lehrnbecher, T; Niemeyer, CM; Reinhardt, D; Reiter, A; Ritter, J; Stary, J; Zimmermann, M | 1 |
| Lambert, WE; Maudens, KE; Wille, SM | 1 |
| Bordessoule, D; Bourhis, JH; Castaigne, S; Contentin, N; de Botton, S; de Revel, T; Dombret, H; Fagot, T; Fenaux, P; Gardin, C; Michallet, M; Pautas, C; Preudhomme, C; Raffoux, E; Reman, O; Terre, C; Thomas, X; Turlure, P | 1 |
| Bijnens, B; Claus, P; D'hooge, J; Eyskens, B; Ganame, J; Gewillig, M; Mertens, L; Renard, M; Sutherland, GR; Uyttebroeck, A | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| Amin, HM; Harb, AJ; Quintás-Cardama, A; Verstovsek, S | 1 |
| Bárdi, E; Bobok, I; Kappelmayer, J; Kiss, C; V Oláh, A | 1 |
| Dragojew, S; Ilnicki, K; Jóźwiak, Z; Marczak, A; Maszewski, J | 1 |
| Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N | 1 |
| Chen, J; Gu, LJ; Li, J; Pan, C; Tang, JY; Xue, HL; Ye, H; Zhao, HJ | 1 |
| Hayakawa, M; Ichihashi, T; Iida, H; Iino, M; Kiyoi, H; Naoe, T; Narimatsu, H; Sawamoto, A; Sugiura, I; Suzuki, R; Takeo, T; Tsuzuki, M; Yanada, M; Yokozawa, T | 1 |
| Brandt, M; Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; Medeiros, LJ; O'Brien, S; Pierce, S; Tsimberidou, AM; Wen, S | 1 |
| Bordessoule, D; Contentin, N; de Revel, T; Dombret, H; Etienne, A; Gardin, C; Malfuson, JV; Rigaudeau, S; Terré, C; Thomas, X; Turlure, P; Vey, N | 1 |
| Marczak, A | 1 |
| Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B | 1 |
| Darzynkiewicz, Z; Halicka, HD; Jayabose, S; Kajstura, M; Levendoglu-Tugal, O; Ozkaynak, MF; Sandoval, C; Seiter, K; Traganos, F | 1 |
| Bhuiyan, H; Bogason, A; Gruber, A; Masquelier, M; Paul, C; Vitols, S | 1 |
| Amadori, S; Baila, L; de Witte, T; Di Raimondo, F; Fazi, P; Ferrara, F; Labar, B; Liso, V; Mandelli, F; Marie, JP; Marmont, F; Meloni, G; Muus, P; Petti, MC; Stasi, R; Suciu, S; Thomas, X; Vignetti, M; Willemze, R; Zittoun, R | 1 |
| Estey, EH; Fujii, N; Riddell, SR; Swanson, HM; Turtle, CJ | 1 |
| Matsumura, I | 1 |
| Miyazaki, Y | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y | 1 |
| Bordessoule, D; Bourhis, JH; Castaigne, S; Chevret, S; Contentin, N; Corm, S; de Revel, T; Dombret, H; Fenaux, P; Gardin, C; Merabet, F; Michallet, M; Pautas, C; Preudhomme, C; Raffoux, E; Reman, O; Rousselot, P; Terré, C; Thomas, X; Turlure, P | 1 |
| Asano, H; Hangaishi, A; Hosoi, M; Kurokawa, M; Takahashi, T; Yamamoto, G | 1 |
| Dessalvi, P; Di Tucci, AA; Emanuele, A; Pettinau, M; Romani, C | 1 |
| Tallman, MS | 1 |
| Bay, JO; Béné, MC; Bernard, M; Bouscary, D; Bulabois, CE; Chevallier, P; Daliphard, S; Delain, M; Fegueux, N; Fornecker, L; Harousseau, JL; Himberlin, C; Ifrah, N; Lioure, B; Luquet, I; Pigneux, A; Recher, C; Turlure, P; Vey, N; Witz, B | 1 |
| Bae, JY; Kim, BK; Kim, HK; Kim, I; Koh, Y; Lee, DS; Park, MH; Park, S; Park, SS; Song, EY; Yoon, SS | 1 |
| Andresen, S; Bolwell, B; Chan, J; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J; Tench, S | 1 |
| Asou, N; Fujieda, A; Fujita, H; Handa, H; Honda, S; Kimura, Y; Kiyoi, H; Miyamura, K; Miyawaki, S; Miyazaki, Y; Nagai, T; Nakaseko, C; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Okumura, H; Sakamaki, H; Shinagawa, K; Takahashi, M; Taniwaki, M; Usui, N; Yagasaki, F; Yamane, T | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Hu, M; Jiang, H; Xia, M | 1 |
| Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Marui, Y; Sawa, N; Sumida, K; Suwabe, T; Takaichi, K; Takemoto, F; Tsuchiya, Y; Ubara, Y; Yamanouchi, M | 1 |
| Dobashi, N; Fujita, H; Kiyoi, H; Kobayashi, Y; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Ohnishi, K; Ohtake, S; Ohwada, C; Sakura, T; Shigeno, K; Takeshita, A; Usui, N; Yahagi, Y | 1 |
| Cao, D; Huang, C; Jing, H; Shen, H; Zhong, L | 1 |
| Solis, EC | 1 |
| Bertoli, S; Cavelier, C; Creancier, L; Dastugue, N; Delabesse, E; Demur, C; Dobbelstein, S; Huguet, F; Huynh, A; Kruczynski, A; LaRochelle, O; Mansat-De Mas, V; Pillon, A; Récher, C; Sarry, A; Sarry, JE; Strzelecki, AC; Vergez, F | 1 |
| de Revel, T; Eddou, H; Foissaud, V; Konopacki, J; Malfuson, JV; Thepenier, C | 1 |
| Chi, M; Estey, E; Lin, A; McQuary, A; Othus, M | 1 |
| Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
| Boissel, N; Bordessoule, D; Castaigne, S; Celli-Lebras, K; Chevret, S; de Botton, S; de Revel, T; Dombret, H; Fenaux, P; Gachard, N; Gardin, C; Pautas, C; Preudhomme, C; Quesnel, B; Raffoux, E; Renneville, A; Terré, C; Thomas, X; Turlure, P | 1 |
| Chen, F; Fan, Z; Feng, R; Guo, X; Huang, F; Liu, X; Meng, F; Shi, P; Xu, B; Zha, J | 1 |
| Attal, M; Bérard, E; Bertoli, S; Dastugue, N; Delabesse, E; Demur, C; Dobbelstein, S; Duchayne, E; Huguet, F; Huynh, A; Laurent, G; Lauwers-Cances, V; Mansat-De Mas, V; Récher, C; Sarry, A; Tavitian, S; Vergez, F | 1 |
| Alonzo, TA; Beyene, J; Lehrnbecher, T; Leibundgut, K; Sung, L; Teuffel, O | 1 |
| Cao, X; Cen, J; Chen, Z; Gu, W; Li, M; Liu, Y; Xiang, L; Xie, X; Zhen, X | 1 |
| Chen, B; Ouyang, J; Wang, J; Xu, JY; Yang, YG; Zhang, QG; Zhou, M; Zhou, RF | 1 |
| Li, XY; Li, Y; Wang, X | 1 |
| Creutzig, U; Dworzak, MN; Reinhardt, D; Ritter, J; Schellong, G; Zimmermann, M | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, MN; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Ritter, J; Sander, A; Schrauder, A; Starý, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M | 1 |
| Altman, J; Czerniak, C; Greenberg, D; Koslosky, M; Mehta, J; Pantiru, M; Pi, J; Trifilio, S; Zhou, Z | 1 |
| Falk, IJ; Fyrberg, A; Gréen, H; Hermanson, M; Höglund, M; Lotfi, K; Nahi, H; Palmqvist, L; Paul, E; Rosenquist, R; Stockelberg, D; Wei, Y | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Handa, H; Hatsumi, N; Jimbo, T; Miyawaki, S; Nojima, Y; Saitoh, T; Sakura, T; Shimizu, H; Takada, S | 1 |
| Béné, MC; Bonmati, C; Bouscary, D; Cahn, JY; Delaunay, J; Dreyfus, F; Escoffre-Barbe, M; Fegueux, N; Guardiola, P; Guièze, R; Guyotat, D; Harousseau, JL; Hunault, M; Ifrah, N; Jourdan, E; Lioure, B; Lissandre, S; Luquet, I; Ojeda-Uribe, M; Pigneux, A; Randriamalala, E; Récher, C; Vey, N | 1 |
| Chung, NG; Jang, W; Kim, M; Lee, JW | 1 |
| Miyawaki, S | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Hofman, J; Malcekova, B; Novotna, E; Skarka, A; Wsol, V | 1 |
| Iacoboni, G; Montesinos, P; Sanz, MA | 1 |
| Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
| Berliner, N; Bittencourt, R; Chauffaille, Mde L; Chiattone, CS; Fagundes, EM; Gallagher, R; Ganser, A; Grimwade, D; Jacomo, RH; Kim, HT; Kwaan, HC; Lima, AS; Lo-Coco, F; Löwenberg, B; Lucena-Araujo, AR; Martinez, L; Melo, RA; Niemeyer, CM; Pagnano, K; Pasquini, R; Rego, EM; Ribeiro, RC; Ruiz-Argüelles, G; Sanz, MA; Schrier, SL; Tallman, MS; Undurraga, MS | 1 |
| Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Devidas, M; Gaynon, PS; Hastings, C; Lu, X; Nachman, JB; Sather, HN; Seibel, NL | 1 |
| Drokov, MIu; Galstian, GM; Kessel'man, SA; Kliasova, GA; Kulikov, SM; Kuz'mina, LA; Obukhova, TN; Paramonova, EV; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Troitskaia, VV; Vasil'eva, VA | 1 |
| Lima, KM; Morais, VD; Onsten, TG; Ribeiro, RA; Sekine, L; Ziegelmann, PK | 1 |
| Hebeda, KM; Janssen, NA; Stevens, WB; van der Velden, WJ | 1 |
| Berliner, N; Bittencourt, R; Brunet, S; De la Serna, J; De Lisa, E; Fagundes, EM; Fernández, P; Ganser, A; González-Campos, J; González-Huerta, AJ; Gutiérrez-Aguirre, H; Holowiecka, A; Jacomo, RH; Kim, HT; Krsnik, I; Lo-Coco, F; Löwenberg, B; Martínez, L; Melo, RA; Montesinos, P; Pagnano, K; Pasquini, R; Rego, EM; Ribeiro, RC; Ribera, JM; Ruiz-Argüelles, GJ; Sanz, MA; Undurraga, MS; Uriarte, MR; Vellenga, E | 1 |
| Chen, J; Li, X; Tan, Y; Xu, S | 1 |
| Boissel, N; Cluzeau, T; Devillier, R; Dombret, H; Kiladjian, JJ; Lengline, E; Raffoux, E; Rey, J; Robin, M; Ronchetti, AM; Sebert, M; Vey, N | 1 |
| Su, YZ; Sun, NT; Wang, CB; Zhou, Y | 1 |
| Baty, J; Chang, GS; Christopher, M; Demeter, RT; DiPersio, JF; Duncavage, EJ; Fronick, C; Fulton, R; Graubert, TA; Griffith, M; Griffith, OL; Heath, SE; Helton, NM; Hundal, J; Ketkar-Kulkarni, S; Klco, JM; Kulkarni, S; Lamprecht, TL; Larson, DE; Ley, TJ; Link, DC; Magrini, V; Mardis, ER; Miller, CA; O'Laughlin, M; Ozenberger, BA; Payton, JE; Petti, A; Radich, JP; Shen, D; Spencer, DH; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Bonkovsky, HL; D'Agostino, RB; Hundley, WG; Jordan, JH; Lamar, ZS; Meléndez, GC; Poole, LB; Porosnicu, M; Vera, T; Whitlock, MC | 1 |
| Jamy, O; Martin, MG; Wiedower, E | 1 |
| Gou, H; Hu, X; Lu, X; Peng, W; Shang, M; Song, X; Ye, Y; Ying, B; Zhang, J; Zhao, Z; Zhou, J; Zhou, Y | 1 |
| Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S | 1 |
| Fang, L; Hu, N; Lin, Y; Pan, L; Qin, T; Qu, S; Ru, K; Wang, J; Xiao, Z; Xing, R; Xu, Z; Zhang, H; Zhang, Y | 1 |
| Appelbaum, FR; Erba, H; Estey, E; Godwin, J; Mukherjee, S; Othus, M; Petersdorf, S; Sekeres, MA | 1 |
| Adam, H; Colle, J; Costello, R; Fanciullino, R; Farnault, L; Ivanov, V; Labiad, Y; Mercier, C; Suchon, P; Venton, G | 1 |
| Chen, Y; Hu, J; Liu, T; Yang, T; Yang, X; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Ding, K; Fu, R; Li, L; Liu, H; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y | 1 |
| Beltrão, EI; Benicio, MT; Bezerra, MA; Bezerra, MF; Coelho-Silva, JL; Lucena-Araujo, AR; Machado, CG; Nascimento, JC; Rego, EM; Rocha, CR | 1 |
| Chen, K; Deng, M; Deng, S; Li, J; Li, P; Li, Y; Wang, Y; Xu, B; Zhang, L; Zhou, Y | 1 |
| Huang, WB; Li, MW; Lin, P; Wang, W; Yang, XN; Yao, HY | 1 |
| Ali, A; Burnett, AK; Cahalin, P; Freeman, S; Hills, RK; Hunter, A; Nielsen, OJ; Russell, NH; Thomas, IF | 1 |
| Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I | 1 |
| Kungwankiattichai, S; Owattanapanich, N; Owattanapanich, W; Ruchutrakool, T; Ungprasert, P | 1 |
| Ashizawa, M; Fujiwara, SI; Hatano, K; Kako, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Kimura, SI; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Sato, K; Shirato, Y; Toda, Y; Yamamoto, C; Yamasaki, R | 1 |
| Baskhaeva, GA; Davidiva, JO; Drokov, MY; Dvirnik, VN; Fidarova, ZT; Galtseva, IV; Gavrilina, OA; Kokhno, AV; Kulikov, SM; Kuzmina, LA; Kuznetsova, SA; Lobaova, TI; Loukianova, IA; Obukhova, TN; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Sudarikov, AB; Troitskaya, VV; Vasilyeva, VA | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M; Woo, JM | 1 |
| Adige, S; Ambulos, NP; Baer, MR; Bentzen, SM; Carter-Cooper, BA; Duffy, A; Emadi, A; Lapidus, RG; Law, JY; Patzke, C; Zou, Y | 1 |
| Borthakur, G; Economides, MP; McCue, D; Pemmaraju, N | 1 |
| Matyszewska, D | 1 |
| Arao, Y; Fujimoto, K; Fukaya, K; Furusawa, K; Haga, T; Hiraiwa, H; Kano, N; Kato, H; Kondo, T; Kuwayama, T; Morimoto, R; Murohara, T; Mutsuga, M; Oishi, H; Okumura, T; Sawamura, A; Shimizu, S; Sugiura, Y; Usui, A; Watanabe, N; Yamaguchi, S; Yokoi, T | 1 |
| Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X | 1 |
| Bielec, K; Hołyst, R; Pasitsuparoad, P; Zhou, Y | 1 |
| Bączek, T; Bień, E; Kowalski, P; Krawczyk, MA; Maliszewska, O; Miękus, N; Olędzka, I; Plenis, A; Rodzaj, W; Treder, N | 1 |
| Wang, D; Wang, ZD; Zhang, CH; Zhang, Q | 1 |
| Michaelis, LC | 1 |
| Mao, Y; Tang, F; Xu, X; Zhu, X | 1 |
| Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF | 1 |
| Al-Kali, A; Alkhateeb, H; Begna, KH; Chen, D; Elliott, MA; Gangat, N; Hogan, WJ; Hook, CC; Ketterling, RP; Litzow, MR; Mangaonkar, A; Pardanani, A; Patnaik, MS; Shah, M; Tefferi, A; Viswanatha, D | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Bai, R; Chang, X; Li, L; Li, Y; Lin, R; Liu, N; Liu, X; Peng, X; Ruan, Y; Tang, R; Wang, X; Wen, S | 1 |
| Feng, B; Fu, JF; Kan, WJ; Li, J; Li, JN; Liu, MM; Luo, GH; Song, N; Tu, YT; Wang, HL; Wei, G; Wu, WB; Xu, GY; Xu, R; Zhou, YB | 1 |
| Bengoudifa, BR; Caillot, D; Cluzeau, T; Farkas, F; Gilotti, G; Griskevicius, L; Hodzic, S; Legrand, O; Luppi, M; Minotti, C; Montesinos, P; Rambaldi, A; Sierra, J; Thomas, X; Venditti, A | 1 |
39 review(s) available for idarubicin and daunorubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Time Factors; Vincristine | 1992 |
Selected pharmacologic characteristics of idarubicin and idarubicinol.
Topics: Animals; Daunorubicin; Humans; Idarubicin | 1992 |
New drugs in acute myelogenous leukemia: a review.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Isomerism; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction; Survival Rate; Tretinoin | 1992 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
Topics: Animals; Cells, Cultured; Daunorubicin; Humans; Idarubicin; Leukemia; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice | 1989 |
Idarubicin in acute leukemia: an effective new therapy for the future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Forecasting; Humans; Idarubicin; Leukemia; Remission Induction | 1989 |
Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Topics: Aclarubicin; Anthraquinones; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Cell Survival; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Heart; Humans; Idarubicin; Leukemia; Menogaril; Mitoxantrone; Naphthacenes; Nogalamycin; Sarcoma; Structure-Activity Relationship | 1986 |
Anthracycline analogs: the past, present, and future.
Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Epirubicin; Female; Guinea Pigs; Heart; Humans; Idarubicin; Male; Menogaril; Mice; Nogalamycin; Rabbits; Rats | 1986 |
[Pharmacokinetics of new anthracyclines].
Topics: Antibiotics, Antineoplastic; Daunorubicin; Doxorubicin; Epirubicin; Humans; Idarubicin | 1988 |
Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Topics: Administration, Oral; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Idarubicin; Infusions, Parenteral; Kinetics; Leukemia | 1986 |
Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Topics: Antibiotics, Antineoplastic; Bone Marrow; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Heart; Humans; Idarubicin; Neoplasms | 1986 |
[Current status of clinical results of new antitumor drugs].
Topics: Aminoacridines; Amsacrine; Anthracyclines; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Benzoquinones; Carboplatin; Carubicin; Cisplatin; Daunorubicin; Doxorubicin; Eflornithine; Epirubicin; Humans; Idarubicin; Mitoxantrone; Naphthacenes; Neoplasms; Organoplatinum Compounds; Ornithine; Ribavirin | 1985 |
A review of idarubicin in acute leukemia.
Topics: Adult; Aged; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Daunorubicin; Europe; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 1993 |
Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Humans; Idarubicin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 1996 |
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis | 1998 |
[Treatment of acute and chronic leukemias].
Topics: Acute Disease; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Daunorubicin; Humans; Idarubicin; Karyotyping; Leukemia; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Transplantation, Autologous; Transplantation, Homologous | 1999 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Splenomegaly; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2001 |
Anthracyclines: recent developments in their separation and quantitation.
Topics: Antibiotics, Antineoplastic; Chromatography, High Pressure Liquid; Daunorubicin; Doxorubicin; Electrophoresis, Capillary; Epirubicin; Idarubicin; Spectrophotometry, Ultraviolet | 2001 |
Central nervous system relapse in acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Methotrexate; Tretinoin | 2002 |
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; France; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2003 |
Toxicity of the topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Epirubicin; Etoposide; Humans; Idarubicin; Leukemia; Middle Aged; Mitoxantrone; Mucositis; Podophyllotoxin; Teniposide; Topoisomerase II Inhibitors; Vascular Diseases | 2005 |
[Standard therapies for acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Remission Induction | 2009 |
[Acute myeloid leukemia trials by Japan Adult Leukemia Study Group (JALSG)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Evidence-Based Medicine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Young Adult | 2009 |
Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.
Topics: Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 2013 |
Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Publication Bias; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Development of a curative treatment within the AML-BFM studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Methotrexate; Multicenter Studies as Topic; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thioguanine; Vincristine | 2013 |
[Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Discovery; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Mutation; Recurrence; Tretinoin; Vincristine | 2014 |
Conventional induction and post-remission therapy in APL: have we arrived?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Mitoxantrone; Multicenter Studies as Topic; Oxides; Remission Induction; Tretinoin | 2014 |
Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction | 2015 |
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Doxorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Randomized Controlled Trials as Topic | 2015 |
Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Odds Ratio; Remission Induction; Treatment Outcome; Young Adult | 2018 |
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2019 |
Topoisomerase II inhibitors in AML: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Salvage Therapy; Topoisomerase II Inhibitors | 2019 |
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Safety; Survival Analysis; Topoisomerase II Inhibitors; Treatment Outcome; United States; Young Adult | 2020 |
Is there an optimal adjunct therapy to traditional cytotoxic induction?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction | 2021 |
The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Calcium; Cardiotoxicity; Daunorubicin; Doxorubicin; Epirubicin; Humans; Idarubicin; Mitochondria; Mitochondrial Proteins; Myocytes, Cardiac; Reactive Oxygen Species | 2022 |
70 trial(s) available for idarubicin and daunorubicin
| Article | Year |
|---|---|
Intensive induction chemotherapy in elderly patients. The BGMT Group.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged | 1992 |
Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; France; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Autologous | 1992 |
Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Drug Administration Schedule; Feasibility Studies; Humans; Idarubicin; Infusions, Intravenous; Italy; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Thioguanine | 1992 |
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 1992 |
Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.
Topics: Administration, Oral; Biological Availability; Daunorubicin; Glycosylation; Humans; Idarubicin; Infusions, Intravenous; Kidney; Kidney Diseases; Liver Neoplasms; Neoplasms | 1992 |
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocytosis; Male; Middle Aged; Remission Induction | 1992 |
Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, Preschool; Daunorubicin; Drug Administration Schedule; Female; Hematopoiesis; Humans; Idarubicin; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Vincristine | 1992 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 1991 |
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Probability | 1991 |
Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
Topics: Administration, Oral; Aged; Biological Availability; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic | 1990 |
Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
Topics: Adolescent; Adult; Child; Child, Preschool; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Infant; Leukemia | 1990 |
A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Remission Induction | 1989 |
Idarubicin in acute leukemia: results of US trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute | 1989 |
Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Random Allocation; Remission Induction | 1989 |
A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction | 1989 |
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
Anthracycline analogs: the past, present, and future.
Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Epirubicin; Female; Guinea Pigs; Heart; Humans; Idarubicin; Male; Menogaril; Mice; Nogalamycin; Rabbits; Rats | 1986 |
Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer.
Topics: Administration, Oral; Aged; Carcinoma, Small Cell; Clinical Trials as Topic; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Kinetics; Lung Neoplasms; Male; Middle Aged; Pilot Projects | 1987 |
Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Topics: Antibiotics, Antineoplastic; Bone Marrow; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Heart; Humans; Idarubicin; Neoplasms | 1986 |
The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Vomiting | 1985 |
Pre-treatment with all-trans retinoic acid accelerates polymorphonuclear recovery after chemotherapy in patients with acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hematopoiesis; Humans; Idarubicin; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Neutrophils; Platelet Count; Premedication; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin | 1994 |
MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cytarabine; Daunorubicin; Drug Resistance; Female; Follow-Up Studies; Gene Expression; Humans; Idarubicin; Leukemia, Myeloid; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Remission Induction; RNA, Neoplasm; Survival Rate; Treatment Outcome | 1993 |
Comparison of survival. Chemotherapeutically treated and untreated older patient with acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Sex Factors; Survival Rate; Thioguanine | 1994 |
[Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1994 |
Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Drug Therapy; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Time Factors; Tretinoin | 1994 |
[A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1993 |
Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid; Male; Remission Induction; Thioguanine | 1994 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Acute Disease; Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged | 1996 |
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Rate | 1996 |
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous | 1996 |
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group.
Topics: Aged; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 1996 |
Anthracycline drugs and MDR expression in human leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Humans; Idarubicin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence | 1996 |
A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Topics: Adolescent; Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Data Interpretation, Statistical; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1996 |
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Individuality; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1997 |
Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Area Under Curve; Chromatography, Liquid; Cross-Over Studies; Daunorubicin; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Spectrometry, Fluorescence | 1997 |
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Prognosis; Remission Induction | 1997 |
Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Daunorubicin; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Survival Analysis; Treatment Outcome | 1997 |
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 1998 |
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma.
Topics: Antibiotics, Antineoplastic; Chromatography, High Pressure Liquid; Daunorubicin; Doxorubicin; Drug Monitoring; Epirubicin; Humans; Idarubicin; Linear Models; Molecular Structure; Reference Values; Reproducibility of Results; Sensitivity and Specificity | 1999 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Treatment Outcome | 2001 |
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Risk Factors; Survival Rate | 2001 |
A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
Topics: Aged; Antibiotics, Antineoplastic; Area Under Curve; Biotransformation; Daunorubicin; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Idarubicin; Japan; Leukocyte Count; Leukopenia; Lymphoma; Male; Middle Aged; Neutropenia | 2001 |
Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Bone Marrow Transplantation; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; New Zealand; Recurrence; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Thioguanine; Treatment Outcome | 2004 |
Risk-adapted induction and consolidation therapy in adults with de novo AML aged
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis | 2004 |
Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Disease-Free Survival; Drug Utilization; Female; Fever; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hospitalization; Humans; Idarubicin; Infection Control; Infections; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Remission Induction; Salvage Therapy; Time Factors; Treatment Outcome; Vincristine | 2004 |
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult L
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Probability; Remission Induction; Risk Assessment; Treatment Outcome; Vincristine; Vindesine | 2005 |
Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Chromatography, High Pressure Liquid; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Idarubicin; Liver Neoplasms; Lung Neoplasms; Soft Tissue Neoplasms | 2006 |
Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Marrow Transplantation; Caspases; Cell Count; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Common Antigens; Leukocyte Count; Lymphocytes; Male; Middle Aged; Prognosis; Remission Induction | 2006 |
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cranial Irradiation; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid; Male; Mitoxantrone; Neutropenia; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Blood Transfusion; Daunorubicin; Disease-Free Survival; Female; Hospitalization; Humans; Idarubicin; Leukemia, Myeloid; Male; Remission Induction; Survival Rate | 2007 |
Clinical outcome of children with newly diagnosed acute lymphoblastic leukemia treated in a single center in Shanghai, China.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Child; Child, Preschool; China; Daunorubicin; Female; Health Care Costs; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Risk Assessment; Treatment Outcome; Vincristine | 2008 |
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid; Survival Rate; Treatment Outcome | 2008 |
Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Cyclosporine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Idarubicin; Inhibitory Concentration 50; K562 Cells; Leukemia, Myeloid, Acute; Male; Rhodamine 123; Time Factors; Treatment Outcome; Verapamil | 2009 |
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Interleukin-2; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Recurrence; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Daunorubicin; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Analysis; Young Adult | 2011 |
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Sialic Acid Binding Ig-like Lectin 3 | 2011 |
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Topics: Aged; Aged, 80 and over; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Proportional Hazards Models; Time; Treatment Outcome | 2013 |
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Topics: Adolescent; Antibiotics, Antineoplastic; Bone Marrow; Child; Child, Preschool; Daunorubicin; Dose-Response Relationship, Drug; Female; Heart Diseases; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liposomes; Male; Multivariate Analysis; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Risk Factors; Treatment Outcome | 2013 |
Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cranial Irradiation; Cyclophosphamide; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, B-Cell; Leukocyte Count; Leukocytosis; Male; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Risk; Treatment Outcome; Vincristine | 2015 |
[Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Mitoxantrone; Russia | 2014 |
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Matched-Pair Analysis; Middle Aged; Risk Factors; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 2016 |
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine | 2022 |
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
Topics: Aged; Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2023 |
318 other study(ies) available for idarubicin and daunorubicin
| Article | Year |
|---|---|
Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport.
Topics: Adenosine Triphosphate; Anthracyclines; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport; Cell Membrane; Daunorubicin; Glutathione; Humans; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1997 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
Topics: Animals; Anopheles; Antimalarials; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Inhibitory Concentration 50; Insect Vectors; Life Cycle Stages; Liver; Malaria; Malaria, Falciparum; Male; Mice; Mice, Inbred C57BL; Plasmodium berghei; Plasmodium falciparum; Treatment Outcome | 2012 |
The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
Topics: | 2013 |
Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.
Topics: Animals; Antineoplastic Agents; Biotransformation; Daunorubicin; Doxorubicin; Female; Idarubicin; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Time Factors; Tissue Distribution | 1979 |
Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry.
Topics: Benzimidazoles; Daunorubicin; DNA; Energy Transfer; Flow Cytometry; Fluorescence; Humans; Idarubicin; Intercalating Agents; Leukemia, Promyelocytic, Acute; Tumor Cells, Cultured | 1992 |
Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Topics: Antibiotics, Antineoplastic; Cell Division; Daunorubicin; DNA Damage; DNA, Neoplasm; Doxorubicin; Epirubicin; Glioma; Humans; Idarubicin; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1992 |
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Topics: Cell Division; Daunorubicin; Drug Resistance; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured; Verapamil | 1992 |
High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids.
Topics: Calibration; Chromatography, High Pressure Liquid; Daunorubicin; Fluorescence; Humans; Idarubicin; Reference Standards | 1992 |
Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.
Topics: Adolescent; Adult; Aged; Cost-Benefit Analysis; Costs and Cost Analysis; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Models, Theoretical; Prospective Studies; Remission Induction; Retrospective Studies | 1991 |
Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin.
Topics: Cyclosporins; Daunorubicin; Doxorubicin; Epirubicin; Free Radicals; Humans; Idarubicin; In Vitro Techniques; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Protein Kinase C; Superoxides; Verapamil | 1990 |
Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
Topics: Adult; Antineoplastic Agents; Cell Division; Daunorubicin; DNA Damage; DNA, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biological Availability; Daunorubicin; Female; Half-Life; Humans; Idarubicin; Injections, Intravenous; Male; Middle Aged; Neoplasms | 1990 |
Effect of anthracycline antibiotics on the reconstituted mitochondrial tricarboxylate carrier.
Topics: Animals; Antibiotics, Antineoplastic; Carrier Proteins; Citrates; Daunorubicin; Doxorubicin; Epirubicin; Idarubicin; Kinetics; Mitochondria, Liver; Rats | 1989 |
Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects.
Topics: Administration, Oral; Aged; Biological Availability; Breast Neoplasms; Daunorubicin; Half-Life; Humans; Idarubicin; Male; Middle Aged | 1989 |
Reversed-phase liquid chromatographic determination of idarubicin and its 13-hydroxy metabolite in human plasma.
Topics: Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Daunorubicin; Humans; Hydrogen-Ion Concentration; Idarubicin; Spectrometry, Fluorescence | 1989 |
Enhanced sensitivity of the rat hepatoma cell to the daunorubicin analogue 4-demethoxydaunorubicin associated with induction of DNA damage.
Topics: Animals; Cell Division; Cell Membrane; Daunorubicin; Deferoxamine; DNA Damage; DNA, Neoplasm; Doxorubicin; Drug Screening Assays, Antitumor; Free Radicals; Idarubicin; Liver Neoplasms, Experimental; Rats; Tumor Cells, Cultured | 1989 |
Comparative study of demethoxydaunorubicin with other anthracyclines on generation of oxygen radicals and clonogenic survival of fibroblasts.
Topics: Animals; Antibiotics, Antineoplastic; Catalase; Cell Line; Cell Survival; Chelating Agents; Clone Cells; Cricetinae; Daunorubicin; Doxorubicin; Electrodes; Epirubicin; Fibroblasts; Free Radicals; Idarubicin; Oxygen; Superoxide Dismutase | 1989 |
Improved high-performance liquid chromatographic method using loop-column extraction for analysis of idarubicin and idarubicinol in plasma.
Topics: Chromatography, High Pressure Liquid; Daunorubicin; Humans; Idarubicin; Time Factors | 1989 |
Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Lung Neoplasms; Middle Aged; Neoplasm Metastasis | 1987 |
Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates.
Topics: Adrenergic beta-Antagonists; Animals; Antibodies, Monoclonal; Cell Division; Cyclandelate; Daunorubicin; DNA Replication; Idarubicin; Mandelic Acids; Mice; Mice, Inbred Strains; Perfusion; Prazosin; Thymoma; Thymus Neoplasms | 1987 |
Effects of three new anthracyclines and doxorubicin on the rat isolated heart.
Topics: Animals; Antibiotics, Antineoplastic; Daunorubicin; Doxorubicin; Epirubicin; Heart; Idarubicin; Male; Myocardial Contraction; Myocardium; Rats; Rats, Inbred Strains | 1987 |
Immunosuppression of graft rejection with idarubicin-monoclonal antibody conjugates by elimination of T cell subsets in vivo.
Topics: Animals; Antibodies, Monoclonal; Antigens, Differentiation, T-Lymphocyte; Antigens, Ly; Antigens, Surface; Daunorubicin; Graft Rejection; Idarubicin; Immunosuppression Therapy; Immunotoxins; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Spleen; T-Lymphocytes; Thy-1 Antigens | 1988 |
Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-epidoxo
Topics: Antibiotics, Antineoplastic; Carcinoma, Small Cell; Daunorubicin; Doxorubicin; Drug Resistance; Humans; Idarubicin; Lung Neoplasms; Mitoxantrone; Naphthacenes; Tumor Stem Cell Assay | 1987 |
Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.
Topics: Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Daunorubicin; Humans; Hydroquinones; Idarubicin; Lung Neoplasms; Quinones | 1987 |
Intravenous administration of cyclophosphamide, methotrexate and 5-fluorouracil in metastatic breast cancer. A pilot study.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Remission Induction; Soft Tissue Neoplasms | 1988 |
4-Demethoxydaunorubicin administered orally in advanced breast cancer. A phase II study.
Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Daunorubicin; Female; Humans; Idarubicin; Middle Aged; Nausea; Soft Tissue Neoplasms; Stomach Ulcer; Vomiting | 1988 |
Cardiovascular effects of doxorubicin (Adriamycin) and 4-demethoxydaunorubicin (Idarubicin) in the conscious rat.
Topics: Animals; Blood Pressure; Daunorubicin; Doxorubicin; Electrocardiography; Heart Rate; Idarubicin; Male; Rats; Rats, Inbred Strains; Time Factors | 1988 |
Phase II trial of idarubicin in patients with advanced lymphoma.
Topics: Antibiotics, Antineoplastic; Bone Marrow Diseases; Daunorubicin; Drug Evaluation; Heart Diseases; Humans; Idarubicin; Lymphoma | 1988 |
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1988 |
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nausea; Thrombocytopenia | 1988 |
Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Drug Evaluation; Fluorouracil; Humans; Idarubicin; Methotrexate; Prednisone; Vincristine | 1988 |
Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Daunorubicin; Drug Evaluation; Female; Heart; Humans; Idarubicin; Leukemia; Liver; Male; Tumor Stem Cell Assay | 1988 |
Radionuclide angiographic monitoring in patients treated with potentially cardiotoxic cytostatic drugs.
Topics: Amsacrine; Antibiotics, Antineoplastic; Daunorubicin; Doxorubicin; Electrocardiography; Epirubicin; Female; Heart; Humans; Idarubicin; Male; Mitoxantrone; Prospective Studies; Radionuclide Angiography; Stroke Volume | 1988 |
Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Topics: Adolescent; Adult; Animals; Cells, Cultured; Daunorubicin; Doxorubicin; Epirubicin; Epithelium; Humans; Idarubicin; L-Lactate Dehydrogenase; Liver; Male; Rats; Rats, Inbred Strains; Species Specificity | 1988 |
Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Cell Division; Cell Line; Cell Survival; Daunorubicin; Humans; Idarubicin; Immunotherapy; Mice; Mice, Inbred Strains; Thymoma; Thymus Neoplasms | 1988 |
Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study.
Topics: Administration, Oral; Animals; Bile; Carbon Radioisotopes; Chromatography, Thin Layer; Daunorubicin; Idarubicin; Injections, Intravenous; Male; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Tissue Distribution | 1986 |
Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Heart; Humans; Idarubicin; Kinetics; Melanoma | 1986 |
A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer.
Topics: Adult; Aged; Daunorubicin; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Idarubicin; Leukocyte Count; Middle Aged; Ovarian Neoplasms | 1986 |
Phase I study of oral idarubicin given with a weekly schedule.
Topics: Administration, Oral; Adult; Aged; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Male; Middle Aged; Neoplasms; Risk; Thrombocytopenia | 1986 |
Phase II trial with oral idarubicin in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Middle Aged; Thrombocytopenia | 1986 |
Oral idarubicin in adult acute leukemia: a preliminary experience.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukocyte Count; Male; Middle Aged | 1986 |
Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Drug Evaluation; Hematologic Diseases; Humans; Idarubicin; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Skin Neoplasms | 1986 |
Clinical pharmacology of 4-demethoxydaunorubicin (DMDR).
Topics: Daunorubicin; Drug Evaluation; Humans; Idarubicin; Leukopenia; Liver Diseases; Metabolic Clearance Rate | 1986 |
Phase II study of idarubicin in advanced cervical carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Bone Marrow; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged; Uterine Cervical Neoplasms | 1986 |
Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1986 |
Determination of anthracycline purity in patient samples and identification of in vitro chemical reduction products by application of a multi-diode array high-speed spectrophotometric detector.
Topics: Anaerobiosis; Antibiotics, Antineoplastic; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Daunorubicin; DNA; Doxorubicin; Humans; Idarubicin; Indicators and Reagents; Naphthacenes; Oxidation-Reduction; Spectrophotometry, Ultraviolet | 1986 |
Preliminary observations on intravenous idarubicin (4-demethoxydaunorubicin) in the chronic and accelerated phase of chronic myelogenous leukemia.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Platelet Count | 1986 |
Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin.
Topics: Administration, Oral; Daunorubicin; Humans; Idarubicin; Infusions, Intravenous; Kinetics; Leukemia | 1986 |
Idarubicin in advanced breast cancer: a phase II study.
Topics: Aged; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Idarubicin; Middle Aged; Neoplasm Metastasis | 1986 |
A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin.
Topics: Adult; Antineoplastic Agents; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Tumor Stem Cell Assay | 1986 |
A pilot study of oral idarubicin in metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Female; Humans; Idarubicin; Male; Melanoma; Middle Aged | 1986 |
Oral idarubicin in non-Hodgkin's lymphomas.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Blood; Daunorubicin; Female; Heart; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1986 |
Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Blood; Carcinoma, Bronchogenic; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Lung Neoplasms; Male; Middle Aged | 1986 |
New anthracycline analogs in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Idarubicin; Middle Aged; Naphthacenes | 1986 |
Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Daunorubicin; Female; Half-Life; Humans; Idarubicin; Infusions, Intravenous; Kinetics; Male; Middle Aged; Neoplasms | 1987 |
Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Daunorubicin; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Idarubicin; Infant; Leukemia; Metabolic Clearance Rate; Neoplasms | 1987 |
Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1987 |
Phase II study of idarubicin in advanced endometrial carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Middle Aged; Uterine Neoplasms | 1987 |
Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin.
Topics: Administration, Oral; Biological Availability; Breast Neoplasms; Daunorubicin; Drug Administration Schedule; Female; Humans; Idarubicin; Injections, Intravenous; Metabolic Clearance Rate | 1987 |
Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idarubicin; Lymphatic Metastasis; Middle Aged; Remission Induction; Soft Tissue Neoplasms | 1987 |
Phase II trial of idarubicin in patients with pancreatic cancer.
Topics: Adult; Aged; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Male; Middle Aged; Pancreatic Neoplasms | 1987 |
Relative cardiotoxicity and cytotoxicity of anthraquinonyl glucosaminosides.
Topics: Aminoglycosides; Animals; Anthraquinones; Cell Division; Cell Line; Cell Survival; Daunorubicin; Doxorubicin; Female; Guinea Pigs; Histamine; Hydroxylation; Idarubicin; In Vitro Techniques; Male; Myocardial Contraction; Neoplasms, Experimental | 1987 |
[A phase I trial of idarubicin by oral administration].
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Idarubicin; Male; Middle Aged; Uterine Neoplasms | 1987 |
Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Cell Nucleus; Daunorubicin; DNA; Doxorubicin; Idarubicin; Leukemia P388; Leukemia, Experimental; Mice; Naphthacenes; Nucleic Acid Conformation | 1987 |
4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Daunorubicin; Drug Resistance; Female; Humans; Idarubicin; Middle Aged; Ovarian Neoplasms | 1987 |
Antitumor activity of new anthracycline analogues in combination with interferon alfa.
Topics: Cell Line; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Drug Synergism; Epirubicin; Female; Humans; Idarubicin; Interferon Type I; Tumor Stem Cell Assay | 1987 |
A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Doxorubicin; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1987 |
Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.
Topics: Adolescent; Antibiotics, Antineoplastic; Child; Child, Preschool; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Lymphoid; Male; Remission Induction | 1987 |
4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male | 1987 |
Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Blast Crisis; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 1987 |
Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1987 |
Pharmacokinetic study of intravenous and oral idarubicin in cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Bile; Biological Availability; Daunorubicin; Female; Humans; Idarubicin; Injections, Intravenous; Male; Middle Aged | 1987 |
Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Daunorubicin; Humans; Idarubicin; Recurrence; Remission Induction; Time Factors | 1987 |
Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Lymphoid; Male; Middle Aged | 1987 |
Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Carcinoma; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1987 |
Serum procollagen-III-peptide as a marker for primary myelofibrosis: effect of anthracyclin.
Topics: Daunorubicin; Humans; Idarubicin; Male; Middle Aged; Peptide Fragments; Primary Myelofibrosis; Procollagen | 1987 |
Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Topics: Antibiotics, Antineoplastic; Biotransformation; Daunorubicin; Humans; Idarubicin; Injections, Intravenous; Kinetics; Leukemia, Myeloid, Acute | 1987 |
Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1987 |
Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells in vitro.
Topics: Antibiotics, Antineoplastic; Bone Marrow; Carubicin; Cell Survival; Daunorubicin; Humans; Idarubicin; In Vitro Techniques; Stem Cells; Tumor Cells, Cultured | 1987 |
Comparative metabolism of daunorubicin and 4-demethoxydaunorubicin in mice and rabbits.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Animals; Antibiotics, Antineoplastic; Cell Line; Chromatography, High Pressure Liquid; Daunorubicin; Idarubicin; In Vitro Techniques; Kinetics; Liver; Mice; Rabbits; Tumor Stem Cell Assay | 1986 |
Idarubicin in refractory acute leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Parenteral; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Neoplasm Metastasis | 1986 |
Synthesis of novel 13-methyl-13-dihydroanthracyclines.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemical Phenomena; Chemistry; Daunorubicin; Idarubicin; Leukemia P388; Mice | 1986 |
Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Kidney Neoplasms; Male; Middle Aged | 1985 |
Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Kinetics; Leukemia; Male; Middle Aged | 1985 |
4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
Topics: Acute Disease; Adolescent; Adult; Daunorubicin; Drug Evaluation; Drug Resistance; Female; Humans; Idarubicin; Leukemia; Leukemia, Lymphoid; Male; Middle Aged; Pilot Projects | 1985 |
Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antineoplastic Agents; Daunorubicin; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia; Lymphoma; Male; Middle Aged; Multiple Myeloma; Pilot Projects | 1985 |
Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Daunorubicin; Drug Evaluation; Female; Granulosa Cell Tumor; Humans; Idarubicin; Middle Aged; Ovarian Neoplasms | 1985 |
Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1985 |
Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Daunorubicin; Female; Humans; Idarubicin; Male; Middle Aged | 1985 |
Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1985 |
Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture.
Topics: Antibiotics, Antineoplastic; Cell Survival; Daunorubicin; Doxorubicin; Epirubicin; Humans; Idarubicin; Kinetics; Metabolic Clearance Rate; Naphthacenes; Solubility; Structure-Activity Relationship; Tissue Distribution | 1985 |
Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
Topics: Administration, Oral; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Injections, Intravenous; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1985 |
Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias.
Topics: Acute Disease; Adult; Antineoplastic Agents; Bone Marrow; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1985 |
Preliminary results in secondary acute non-lymphocytic leukemia (ANLL) treated with Idarubicin.
Topics: Adult; Aged; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local | 1985 |
Synthesis and antitumor activity of optically active (+)-9-O-alpha-L-daunosaminyl-4-demethoxydaunorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Daunorubicin; Idarubicin; Leukemia P388; Mice | 1985 |
Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Daunorubicin; Digestive System; Drug Evaluation; Heart; Humans; Idarubicin; Leukopenia; Lung Neoplasms; Middle Aged | 1984 |
Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Cell Survival; Cricetinae; Cricetulus; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Escherichia coli; Idarubicin; Mutagens; Salmonella typhimurium | 1984 |
Novel mode of cytotoxicity obtained by coupling inactive anthracycline to a polymer.
Topics: Animals; Antibiotics, Antineoplastic; Daunorubicin; Glutaral; Idarubicin; Leukemia L1210; Microspheres; Polymers | 1984 |
Total chemical synthesis and antitumor evaluation of 4-demethoxy-10,10-dimethyldaunomycin.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Daunorubicin; Doxorubicin; Drug Evaluation, Preclinical; Idarubicin; Indicators and Reagents; Leukemia P388; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Inbred DBA | 1984 |
Toxicological studies with a novel synthetic anthracycline, the bis-hydrazone bridged analog of 4-demethoxydaunorubicin (SC-33428).
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Body Weight; Daunorubicin; Doxorubicin; Electrocardiography; Female; Idarubicin; Leukopenia; Rats; Rats, Inbred Strains; Time Factors | 1984 |
Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
Topics: Animals; Antineoplastic Agents; Daunorubicin; Doxorubicin; Idarubicin; Leukemia L1210; Leukemia P388; Lung Neoplasms; Melanoma; Mice; Neoplasms, Experimental | 1983 |
High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Daunorubicin; Fluorescence; Half-Life; Humans; Idarubicin; Injections, Intravenous; Kinetics | 1983 |
Uptake kinetics and intracellular distribution of anthracyclines studied by laser cytofluorometry.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Nucleus; Cytoplasm; Daunorubicin; HeLa Cells; Humans; Idarubicin; Kinetics; Lasers; Naphthacenes; Spectrometry, Fluorescence | 1983 |
Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Lymphoma; Middle Aged | 1983 |
Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Immunosuppression Therapy; Injections, Intravenous; Kinetics; Male; Middle Aged; Neoplasms | 1983 |
Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged; Time Factors | 1983 |
Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Male; Middle Aged; Rectal Neoplasms | 1984 |
Complete remission in prolymphocytic leukemia with 4-demethoxydaunorubicin and arabinosyl cytosine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Lymphoid; Leukocyte Count; Male; Middle Aged; Prednisone; Splenomegaly; Vincristine | 1984 |
Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors.
Topics: Administration, Oral; Animals; Daunorubicin; Doxorubicin; Drug Administration Schedule; Female; Half-Life; Idarubicin; Injections, Intravenous; Kinetics; Lymphoma; Male; Mice; Neoplasm Transplantation; Tissue Distribution | 1984 |
[Adriamycin and its analogs].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Chemical Phenomena; Chemistry; Daunorubicin; DNA, Neoplasm; Doxorubicin; Epirubicin; Humans; Idarubicin; Stereoisomerism | 1984 |
Self-association of doxorubicin and related compounds in aqueous solution.
Topics: Chemistry, Pharmaceutical; Daunorubicin; Doxorubicin; Epirubicin; Idarubicin; Solutions; Spectrophotometry | 1984 |
Phase I study of 4-demethoxydaunorubicin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Daunorubicin; Digestive System; Drug Evaluation; Female; Humans; Idarubicin; Injections, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1983 |
Phase II study of 4-demethoxydaunorubicin in patients with adenocarcinoma of the upper gastrointestinal tract.
Topics: Adenocarcinoma; Daunorubicin; Drug Evaluation; Esophageal Neoplasms; Humans; Idarubicin; Stomach Neoplasms | 1984 |
Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Blood; Daunorubicin; Drug Evaluation; Female; Heart; Humans; Idarubicin; Male; Middle Aged; Neoplasms | 1984 |
Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Idarubicin; Leukemia; Leukopenia; Male; Middle Aged | 1984 |
Selective mitochondrial alterations induced by a single dose of daunorubicin or 4-demethoxydaunorubicin in mouse ventricular myocardium.
Topics: Animals; Cardiomyopathies; Daunorubicin; Endoplasmic Reticulum; Heart; Idarubicin; Male; Mice; Microscopy, Electron; Mitochondria, Heart; Myocardium | 1980 |
Antileukemic activity of 4-demethoxydaunorubicin in mice.
Topics: Administration, Oral; Animals; Daunorubicin; Doxorubicin; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Idarubicin; Injections, Intravenous; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Male; Mice | 1980 |
Hematopoietic precursor cells in mice treated with 4-demethoxydaunorubicin and doxorubicin.
Topics: Animals; Cell Survival; Colony-Forming Units Assay; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Erythrocytes; Hematopoietic Stem Cells; Idarubicin; Mice; Mice, Inbred C57BL; Reticulocytes; Time Factors | 1982 |
Phase I trial of 4-demethoxydaunorubicin with single i.v. doses.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idarubicin; Kinetics; Male; Middle Aged; Neoplasms | 1982 |
The discovery of daunorubicin.
Topics: Animals; Chemistry; Daunorubicin; DNA; Doxorubicin; History, 20th Century; Idarubicin; Italy; Mice; Neoplasms, Experimental; Rats; Stereoisomerism | 1981 |
Synthesis of 4-demethoxy-11-deoxy-analogs of daunomycin and adriamycin.
Topics: Animals; Cell Division; Cells, Cultured; Daunorubicin; DNA, Neoplasm; Doxorubicin; Idarubicin; Leukemia L1210; RNA, Neoplasm; Structure-Activity Relationship | 1980 |
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Breast Neoplasms; Cell Survival; Culture Media; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Stability; HL-60 Cells; Humans; Idarubicin; Intracellular Fluid; Tumor Cells, Cultured | 1995 |
Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors.
Topics: Aged; Aged, 80 and over; Blood Cells; Bone Marrow Cells; Cells, Cultured; Culture Techniques; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Recombinant Proteins; Tumor Cells, Cultured | 1995 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Blood Cell Count; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Gene Expression; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 1995 |
The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Death; Cell Membrane Permeability; Chromatography, High Pressure Liquid; Cytosol; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Surface-Active Agents; Tumor Cells, Cultured | 1995 |
Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Doxorubicin; Echocardiography, Doppler, Color; Enalapril; Female; Gated Blood-Pool Imaging; Heart Failure; Humans; Idarubicin; Leukemia; Male; Middle Aged; Radiation Injuries; Radiotherapy; Ventricular Dysfunction, Left; Ventricular Function, Left | 1995 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Bone Marrow; Child; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance; Humans; Idarubicin; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1995 |
Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Mice; Transfection | 1995 |
Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
Topics: Antibiotics, Antineoplastic; Base Sequence; Daunorubicin; DNA; DNA Topoisomerases, Type II; Doxorubicin; Idarubicin; Molecular Sequence Data; Structure-Activity Relationship | 1995 |
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Immunologic Factors; Leukemia, Promyelocytic, Acute; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Neutropenia; Nuclear Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Analysis; Transcription Factors; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 1995 |
Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Rhodamine 123; Rhodamines; Survival Analysis | 1995 |
In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Survival; Cells, Cultured; Cyclosporine; Daunorubicin; Drug Resistance; Drug Resistance, Multiple; Female; Fluorescent Antibody Technique; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Reference Values | 1994 |
Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Topics: Affinity Labels; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Biological Transport; Cell Membrane; Cell Nucleus; Clone Cells; Colonic Neoplasms; Daunorubicin; Dihydropyridines; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Fluorescence; Humans; Idarubicin; Tumor Cells, Cultured | 1994 |
Influence of idarubicinol on the antileukemic effect of idarubicin.
Topics: Daunorubicin; DNA; DNA Damage; Humans; Idarubicin; In Vitro Techniques; Leukemia, Myeloid; Nucleic Acid Synthesis Inhibitors; Tumor Cells, Cultured | 1994 |
Daunorubicin (DNR) accumulation in fresh leukemic cells: correlation with clinical and biological features.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Stimulation, Chemical; Treatment Failure; Verapamil | 1994 |
Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Nucleus; Cell Survival; Daunorubicin; DNA; Humans; Idarubicin; Lethal Dose 50; Lymphocytes; Tumor Cells, Cultured | 1994 |
A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colonic Neoplasms; Daunorubicin; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Gene Expression; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Tumor Cells, Cultured | 1993 |
D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cell Survival; Colonic Neoplasms; Daunorubicin; Doxorubicin; Drug Interactions; Drug Resistance; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Tumor Cells, Cultured; Verapamil | 1993 |
Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
Topics: Acute Disease; Antineoplastic Agents; Cell Division; Daunorubicin; Doxorubicin; Granulocytes; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myeloid; Macrophages; Tumor Stem Cell Assay | 1994 |
Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
Topics: Acute Disease; Aged; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 1994 |
Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
Topics: Adolescent; Adult; Daunorubicin; Drug Resistance; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Tumor Cells, Cultured; Verapamil | 1994 |
[The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Hematopoiesis; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisolone; Remission Induction; Time Factors; Vincristine | 1993 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; Prognosis; Remission Induction; Time Factors | 1993 |
Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells.
Topics: Daunorubicin; Humans; Idarubicin; Leukemia; Tumor Cells, Cultured | 1993 |
Effect of doxorubicin, daunorubicin, and idarubicin on the growth rate of human leukemia cells (K562) studied with image analysis.
Topics: Cell Division; Daunorubicin; Doxorubicin; Growth Inhibitors; Humans; Idarubicin; Image Processing, Computer-Assisted; In Vitro Techniques; Tumor Cells, Cultured | 1993 |
P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia.
Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase | 1995 |
Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Recurrence; Translocation, Genetic | 1996 |
Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo.
Topics: Antigens, CD34; Daunorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Leukemia, Myeloid, Acute; Morpholines; Rhodamine 123; Rhodamines; Triamterene | 1996 |
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cell Membrane Permeability; Cell Nucleus; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Microbial Sensitivity Tests; Tumor Cells, Cultured | 1996 |
Comparison of DNA sequence selectivity of anthracycline antibiotics and their 3'-hydroxylated analogs.
Topics: Antibiotics, Antineoplastic; Base Composition; Base Sequence; Daunorubicin; Deoxyribonuclease I; DNA; DNA Footprinting; Doxorubicin; Idarubicin; Intercalating Agents; Kinetics; Molecular Sequence Data; Molecular Structure | 1996 |
Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Daunorubicin; DNA Topoisomerases, Type II; Etoposide; Humans; Hydrogen-Ion Concentration; Idarubicin; Leukemia, Myeloid, Acute; Podophyllotoxin; Precipitin Tests; Topoisomerase II Inhibitors | 1996 |
Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blast Crisis; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Hydrogen-Ion Concentration; Idarubicin; Isoenzymes; Leukemia, Myeloid, Acute; Poly-ADP-Ribose Binding Proteins; Prognosis; Tumor Cells, Cultured | 1996 |
Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Tumor Cells, Cultured | 1996 |
Marked bone marrow eosinophilia at the time of relapse of acute myeloblastic leukaemia in association with the appearance of translocation t(12;20)(q24;q11).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Eosinophilia; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Translocation, Genetic | 1996 |
Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Division; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; HL-60 Cells; Humans; Idarubicin | 1996 |
A comparison of a CB17 scid mouse model and the tetrazolium-dye assay using human haematological tumour cell lines.
Topics: Animals; Antineoplastic Agents; Burkitt Lymphoma; Coloring Agents; Daunorubicin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Experimental; Male; Mice; Mice, SCID; Multiple Myeloma; Tetrazolium Salts; Toxicity Tests; Tumor Cells, Cultured | 1996 |
Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.
Topics: Bone Marrow; Daunorubicin; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Humans; Idarubicin; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Topoisomerase II Inhibitors | 1997 |
Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Buthionine Sulfoximine; Calcium Channel Blockers; Cyclosporins; Daunorubicin; Humans; Idarubicin; Leukemia, T-Cell; Multidrug Resistance-Associated Proteins; Rhodamine 123; Rhodamines; Tumor Cells, Cultured; Verapamil | 1996 |
Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Idarubicin; Immunosuppressive Agents; Tumor Cells, Cultured | 1996 |
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.
Topics: Acridines; Amsacrine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine Sulfoximine; Cell Line; Cell Survival; Daunorubicin; Drug Resistance, Multiple; HL-60 Cells; Humans; Idarubicin; Leukemia; Paclitaxel; Phenotype; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Verapamil | 1997 |
Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
Topics: Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Fluorescent Dyes; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhodamines | 1997 |
Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Idarubicin; Kinetics; Leukemia; Mitoxantrone | 1997 |
Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
Topics: Animals; Antibiotics, Antineoplastic; Chromatography, High Pressure Liquid; Daunorubicin; Idarubicin; Rabbits; Tissue Distribution | 1997 |
Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cytarabine; Daunorubicin; Ear Canal; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Neoplasm Proteins; Oncogene Proteins, Fusion; Radiotherapy; Recurrence; Remission Induction; Salvage Therapy; Tretinoin; Vindesine | 1997 |
Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.
Topics: 2,4-Dinitrophenol; Antibiotics, Antineoplastic; Antimetabolites; Binding Sites; Biological Transport; Biological Transport, Active; Carrier Proteins; Cells, Cultured; Daunorubicin; Diffusion; Dose-Response Relationship, Drug; Doxorubicin; HL-60 Cells; Humans; Idarubicin; Monocytes; Temperature | 1997 |
Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
Topics: Antibiotics, Antineoplastic; Child; Daunorubicin; Electrophoresis, Capillary; Humans; Idarubicin; Reference Standards | 1997 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Chromatography, High Pressure Liquid; Daunorubicin; Half-Life; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged; Regression Analysis | 1997 |
Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Nucleus; Daunorubicin; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Idarubicin; Leukemia | 1998 |
Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study.
Topics: Anthracyclines; Circular Dichroism; Daunorubicin; Dimerization; Doxorubicin; Idarubicin; Lipid Bilayers; Liposomes; Membranes, Artificial; Models, Molecular; Solvents | 1998 |
The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Daunorubicin; Doxorubicin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Idarubicin; Leukemia; Tumor Cells, Cultured; Verapamil | 1998 |
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1998 |
Only association of low concentrations of idarubicin plus idarubicinol induced apoptosis on leukaemic cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Daunorubicin; HL-60 Cells; Humans; Idarubicin | 1998 |
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Topics: Antineoplastic Agents; Cell Division; Cell Extracts; Cell Survival; Cytotoxins; Daunorubicin; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Idarubicin; Trypan Blue; Tumor Cells, Cultured | 1998 |
[Successful emergency operation for massive hemorrhage due to jejunal angiodysplasia after intensive chemotherapy in a patient with refractory anemia with excess of blasts].
Topics: Anemia, Refractory, with Excess of Blasts; Angiodysplasia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Therapy, Combination; Emergencies; Enterocolitis; Gastrointestinal Hemorrhage; Humans; Idarubicin; Jejunal Diseases; Male; Mercaptopurine; Middle Aged; Neutropenia; Prednisolone; Vincristine | 1998 |
Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Female; Gene Amplification; Gene Rearrangement; Humans; Idarubicin; Immunophenotyping; Leukemia, Promyelocytic, Acute; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Skin Neoplasms; Translocation, Genetic; Tretinoin | 1998 |
Orientation of anthracyclines in lipid monolayers and planar asymmetrical bilayers: a surface-enhanced resonance Raman scattering study.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Doxorubicin; Idarubicin; Lipid Bilayers; Molecular Structure; Phosphatidic Acids; Phosphatidylcholines; Phospholipids; Pressure; Scattering, Radiation; Spectrum Analysis, Raman; Surface Properties | 1998 |
Management of acute promyelocytic leukemia relapse in the ATRA era.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Thioguanine; Treatment Outcome; Tretinoin | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Humans; Idarubicin; K562 Cells | 1999 |
A single apheresis to achieve a high number of peripheral blood CD34+ cells in a lithium-treated patient with acute myeloid leukaemia.
Topics: Adult; Antigens, CD34; Antimanic Agents; Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Blood Cell Count; Cytarabine; Daunorubicin; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Idarubicin; Leukapheresis; Leukemia, Monocytic, Acute; Lithium Carbonate; Mitoxantrone; Recombinant Proteins; Remission Induction; Thioguanine | 1999 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Long-term molecular remission in promyelocytic transformation of myeloproliferative disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Polycythemia Vera; Preleukemia; Prognosis; Remission Induction; Thrombocythemia, Essential; Thrombophilia; Translocation, Genetic; Tretinoin | 1999 |
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Idarubicin; Immunosuppressive Agents; Leukemia; Tumor Cells, Cultured | 1999 |
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Idarubicin; Multiple Myeloma; Tumor Cells, Cultured; Verapamil | 1999 |
Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.
Topics: Animals; Antibiotics, Antineoplastic; Chromatography, High Pressure Liquid; Daunorubicin; Idarubicin; Male; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 1999 |
Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
Topics: Anthracyclines; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytosol; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Humans; Idarubicin; K562 Cells; Photoaffinity Labels; Ultraviolet Rays; Verapamil | 1999 |
How Fe3+ binds anthracycline antitumour compounds. The myth and the reality of a chemical sphinx.
Topics: Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Circular Dichroism; Daunorubicin; Doxorubicin; Humans; Hydrogen-Ion Concentration; Idarubicin; Iron; Methanol; Spectrophotometry, Ultraviolet; Sulfonic Acids; Water | 1999 |
Contribution of the nucleoside transport system to doxorubicin transport in HL60 cells but not in mononuclear cells.
Topics: Antibiotics, Antineoplastic; Biological Transport; Carrier Proteins; Daunorubicin; Doxorubicin; Drug Interactions; HL-60 Cells; Humans; Idarubicin; In Vitro Techniques; Leukemia; Leukocytes, Mononuclear; Membrane Proteins; Nucleoside Transport Proteins; Sodium | 1999 |
Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Pair Mismatch; Benzimidazoles; Daunorubicin; DNA-Binding Proteins; Energy Transfer; Flow Cytometry; Fluorescent Dyes; Humans; Idarubicin; Intercalating Agents; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Rhodamines; Sensitivity and Specificity; Spectrometry, Fluorescence; Tumor Cells, Cultured | 1999 |
Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.
Topics: Antibiotics, Antineoplastic; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow Cells; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Daunorubicin; Drug Resistance, Multiple; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Idarubicin; Idoxuridine; Leukemia, Myeloid, Acute; Verapamil | 1999 |
The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Idarubicin; Immunohistochemistry; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Survival Rate; Tretinoin; Vault Ribonucleoprotein Particles | 1999 |
Apoptosis by anthracyclines at therapeutic concentrations in MDR1+ human leukemic cells.
Topics: Annexin A5; Antibiotics, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Genes, MDR; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Membrane Lipids; Necrosis; Phosphatidylserines; Tumor Cells, Cultured | 1999 |
In vitro transepithelial drug transport by on-line measurement: cellular control of paracellular and transcellular transport.
Topics: Algorithms; Animals; Biological Transport, Active; Cattle; Cell Line; Cells, Cultured; Chemical Phenomena; Chemistry, Physical; Cyclosporins; Daunorubicin; Dextrans; Dogs; Epithelial Cells; Fluorescein-5-isothiocyanate; Genes, MDR; Humans; Idarubicin; Models, Biological; Online Systems; Tight Junctions | 1999 |
The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Biological Transport, Active; Cell Compartmentation; Cell Line; Cell Membrane Permeability; Daunorubicin; Digitonin; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Humans; Idarubicin; Kinetics; Verapamil | 2000 |
In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Calcium Channel Blockers; Daunorubicin; Dihydropyridines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Verapamil | 2000 |
Induction of apoptosis by idarubicin: how important is the plasma peak?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Area Under Curve; Daunorubicin; DNA, Neoplasm; HL-60 Cells; Humans; Idarubicin; Leukemia, Promyelocytic, Acute | 2000 |
Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells.
Topics: Adult; Annexin A5; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Apoptosis; Biomarkers; Blotting, Western; Bone Marrow Cells; Camptothecin; Caspase 3; Caspase 7; Caspases; Daunorubicin; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Humans; Idarubicin; Leukemia; Peptide Hydrolases; Protein Binding; U937 Cells | 2000 |
Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liver Neoplasms; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Prednisolone; Remission Induction; Reoperation | 2000 |
Interferon may reduce minimal residual disease of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Interferons; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Recurrence; Remission Induction; Tretinoin | 2000 |
Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Caspase 3; Caspases; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; fas Receptor; Female; Flow Cytometry; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Peptide Hydrolases; Prognosis; Remission Induction; Signal Transduction; Survival Analysis; Treatment Outcome | 2000 |
Treatment of anthracycline extravasation with dexrazoxane.
Topics: Animals; Antibiotics, Antineoplastic; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Extravasation of Diagnostic and Therapeutic Materials; Female; Idarubicin; Mice; Razoxane; Skin Diseases; Topoisomerase II Inhibitors | 2000 |
In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Asparaginase; Bone Marrow Cells; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Infant; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Statistics, Nonparametric; Teniposide; Thioguanine; Vincristine | 2000 |
Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Dosage Compensation, Genetic; Female; Follow-Up Studies; Hematopoiesis; Humans; Idarubicin; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Retrospective Studies; Thioguanine; Time Factors | 2000 |
Simultaneous determination of doxorubicin, daunorubicin, and idarubicin by capillary electrophoresis with laser-induced fluorescence detection.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Doxorubicin; Electrophoresis, Capillary; Fluorescence; Humans; Idarubicin; Lasers; Molecular Structure | 2001 |
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Daunorubicin; Female; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Prospective Studies; Recurrence | 2001 |
[Acute myeloid leukemia in the adult. Results of the National Antineoplastic Drug Protocol at the Hospital del Salvador, 1990-1998].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Retrospective Studies; Treatment Outcome | 2000 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Tretinoin | 2001 |
Spectroscopic studies on iron complexes of different anthracyclines in aprotic solvent systems.
Topics: Antibiotics, Antineoplastic; Circular Dichroism; Daunorubicin; Dimethylformamide; Doxorubicin; Electron Spin Resonance Spectroscopy; Ferric Compounds; Fluorometry; Idarubicin; Spectrophotometry, Ultraviolet; Spectroscopy, Mossbauer | 2001 |
An adjustment for a post-randomization variable in the comparison of two treatments for survival.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Likelihood Functions; Models, Biological; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2001 |
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Calcium Channel Blockers; Carbocyanines; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Genistein; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Probenecid; Prognosis; Prospective Studies; Rhodamine 123; Survival Analysis; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Verapamil | 2002 |
Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.
Topics: Algorithms; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Daunorubicin; Heart; Idarubicin; In Vitro Techniques; Male; Myocardium; Rats; Rats, Sprague-Dawley; Stroke Volume; Verapamil | 2001 |
Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Caspases; Child; Child, Preschool; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Daunorubicin; Dexamethasone; Enzyme Induction; Etoposide; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genes, bcl-2; Genes, p53; Humans; Idarubicin; Infant; Male; Neoplasm Proteins; Neoplastic Stem Cells; Nuclear Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Thioguanine; Tumor Suppressor Protein p53; Vincristine | 2002 |
Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Cardiolipins; Chickens; Creatine Kinase; Creatine Kinase, Mitochondrial Form; Daunorubicin; Doxorubicin; Heart; Humans; Idarubicin; Isoenzymes; Models, Molecular; Molecular Weight; Myocardium | 2002 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |
Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Survival; Daunorubicin; Drug Resistance; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia; Tumor Cells, Cultured | 2002 |
Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
Topics: Animals; Antibiotics, Antineoplastic; Daunorubicin; Drug Administration Routes; Drug Carriers; Duodenum; Idarubicin; Nanotechnology; Rats; Rats, Wistar; Solutions; Tissue Distribution | 2002 |
Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.
Topics: Antibiotics, Antineoplastic; Catalytic Domain; Daunorubicin; DNA; DNA Topoisomerases, Type II; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; Idarubicin; K562 Cells; Leukemia; Topoisomerase II Inhibitors | 2002 |
The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Topics: Adolescent; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Child, Preschool; Daunorubicin; Flow Cytometry; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tetrazolium Salts; Thiazoles | 2002 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
New designs for phase 2 clinical trials.
Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome | 2003 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital.
Topics: Amiodarone; Animals; Antineoplastic Agents; Daunorubicin; Drug Design; Excitatory Amino Acid Antagonists; Heart; Idarubicin; Kinetics; Male; Phenobarbital; Rats; Rats, Sprague-Dawley; Rutin; Time Factors; Vasodilator Agents; Verapamil | 2003 |
Morphological and biochemical changes in human fibroblast lines induced by anthracyclines during apoptosis.
Topics: Aclarubicin; Anthracyclines; Apoptosis; Calcium; Caspase 3; Caspases; Cell Line; Daunorubicin; Enzyme Activation; Fibroblasts; Humans; Idarubicin; Intracellular Fluid; Trisomy | 2003 |
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Topics: Acute Disease; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Daunorubicin; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Risk Factors; Tandem Repeat Sequences | 2003 |
A case of leukemia of the appendix presenting as acute appendicitis.
Topics: Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendicitis; Appendix; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mercaptopurine; Sarcoma, Myeloid | 2003 |
In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.
Topics: Acute Disease; Adult; Aged; Annexin A5; Anthracyclines; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Daunorubicin; Female; Humans; Idarubicin; K562 Cells; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Middle Aged; Propidium; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cells, Cultured; Daunorubicin; Doxorubicin; Epirubicin; Group VI Phospholipases A2; Heart Ventricles; Idarubicin; Myocytes, Cardiac; Oxidative Stress; Phospholipases A; Phospholipases A2; Rats; Rats, Sprague-Dawley | 2003 |
Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Cytogenetic Analysis; Daunorubicin; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Male; Prednisone; Retrospective Studies; Treatment Outcome; Vincristine | 2003 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2003 |
Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test.
Topics: Aclarubicin; Animals; Biological Assay; Daunorubicin; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drosophila; Idarubicin; Mutagenesis; Topoisomerase Inhibitors; Wings, Animal | 2004 |
Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Area Under Curve; Daunorubicin; Female; Humans; Idarubicin; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2004 |
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Proliferation; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Rate | 2004 |
Thiol oxidation induced by oxidative action of adriamycin.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Benzoquinones; Creatine Kinase; Daunorubicin; Doxorubicin; Electron Spin Resonance Spectroscopy; Epirubicin; Free Radicals; Glutathione; Horseradish Peroxidase; Hydrogen Peroxide; Hypoxanthine; Idarubicin; Oxidation-Reduction; Sulfhydryl Compounds; Xanthine Oxidase | 2004 |
Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery.
Topics: Animals; Antibiotics, Antineoplastic; Aorta, Thoracic; Coronary Circulation; Daunorubicin; Dose-Response Relationship, Drug; Heart; Idarubicin; In Vitro Techniques; Inhibitory Concentration 50; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Norepinephrine; Phenylephrine; Potassium Chloride; Rats; Rats, Wistar; Vascular Resistance; Vasoconstriction; Vasoconstrictor Agents | 2006 |
Idarubicin and idarubicinol effects on breast cancer multicellular spheroids.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Inhibitory Concentration 50; Spheroids, Cellular; Time Factors | 2005 |
Traces of phosgene in chloroform: consequences for extraction of anthracyclines.
Topics: Amines; Anthracyclines; Chloroform; Chromatography, Liquid; Daunorubicin; Doxorubicin; Epirubicin; Ethanol; Idarubicin; Molecular Structure; Phosgene; Reproducibility of Results; Solvents; Spectrometry, Fluorescence | 2007 |
Acute cardiac functional and morphological changes after Anthracycline infusions in children.
Topics: Adolescent; Anthracyclines; Antibiotics, Antineoplastic; Blood Flow Velocity; Blood Pressure; Child; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography, Doppler; Female; Heart Rate; Humans; Idarubicin; Infusions, Intravenous; Male; Myocardial Contraction; Neoplasms; Observer Variation; Prospective Studies; Reproducibility of Results; Research Design; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2007 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
Granulocytic sarcoma with massive scalp involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Back; Bone Marrow; Cytarabine; Daunorubicin; Fatal Outcome; Female; Humans; Idarubicin; Leukemic Infiltration; Meninges; Pravastatin; Sarcoma, Myeloid; Scalp; Skin | 2008 |
Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
Topics: Acetylglucosaminidase; Adolescent; Adult; Albuminuria; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Child; Child, Preschool; Creatinine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Idarubicin; Infant; Kidney Diseases; Kidney Tubules, Proximal; Lymphoma, Non-Hodgkin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Retrospective Studies | 2007 |
The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts.
Topics: Apoptosis; Calcium; Caspase 3; Cell Line; Daunorubicin; Diabetes Mellitus, Type 2; Enzyme Activation; Fibroblasts; Humans; Idarubicin; Inhibitory Concentration 50; Intracellular Space; Membrane Potential, Mitochondrial; Trisomy | 2008 |
[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Evidence-Based Medicine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vincristine | 2007 |
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Dosage; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Proto-Oncogene Proteins; Recurrence; Remission Induction; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2008 |
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Cytogenetic Analysis; Daunorubicin; Decision Making; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Patient Selection; Practice Guidelines as Topic; Risk Factors; Survival Analysis | 2008 |
Fluorescence anisotropy of membrane fluidity probes in human erythrocytes incubated with anthracyclines and glutaraldehyde.
Topics: Anthracyclines; Daunorubicin; Erythrocytes; Fluorescence Polarization; Glutaral; Humans; Idarubicin; Lipid Bilayers; Membrane Fluidity; Molecular Probe Techniques | 2009 |
DNA damage response as a biomarker in treatment of leukemias.
Topics: Adolescent; Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Cell Cycle Proteins; Child; Daunorubicin; DNA Damage; DNA Topoisomerases; DNA-Binding Proteins; Enzyme Inhibitors; Histones; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Topoisomerase Inhibitors; Tumor Suppressor Proteins | 2009 |
Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Apoptosis; Daunorubicin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Tumor Cells, Cultured; Young Adult | 2009 |
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy.
Topics: Antibiotics, Antineoplastic; CD8-Positive T-Lymphocytes; Cell Proliferation; Cytotoxicity, Immunologic; Daunorubicin; Down-Regulation; Homeostasis; Humans; Idarubicin; Immunologic Memory; Lymphocyte Activation; T-Lymphocyte Subsets | 2009 |
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Gemtuzumab; HL-60 Cells; Humans; Idarubicin; Immunotoxins; Leukemia; Mercaptopurine; Methotrexate; Mitoxantrone; Sialic Acid Binding Ig-like Lectin 3; U937 Cells; Vincristine | 2009 |
Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Leukemia, Monocytic, Acute; Male; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Remission Induction | 2010 |
Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Injections, Spinal; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Male; Meninges; Middle Aged; Mitoxantrone; Testis; Young Adult | 2010 |
Updates on the treatment of acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cytarabine; Daunorubicin; Hemorrhage; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Tetrahydronaphthalenes; Tretinoin | 2010 |
Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Trisomy; Young Adult | 2010 |
Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
[NT-pro-BNP in the evaluation of daunorubicin-indued cardiotoxicity in acute childhood leukemia].
Topics: Anthracyclines; Cardiotoxicity; Daunorubicin; Humans; Idarubicin; Leukemia | 2010 |
Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Middle Aged; Mitomycin; Remission Induction; Renal Dialysis; Tretinoin | 2011 |
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Antibiotics, Antineoplastic; Cells, Cultured; Daunorubicin; Drug Resistance, Neoplasm; Humans; Idarubicin; Ketones; Oxidation-Reduction | 2011 |
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
Topics: Adolescent; Adult; Aged; Animals; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mice; Mice, SCID; Middle Aged; Mutation; Nucleophosmin; Prognosis; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult | 2011 |
Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis | 2012 |
Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fever; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Neutropenia; Obesity; Outcome Assessment, Health Care; Prognosis; Remission Induction; Young Adult | 2013 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; RNA, Messenger | 2013 |
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Time-to-Treatment; Treatment Outcome; Young Adult | 2013 |
The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; Nucleophosmin; Peripheral Blood Stem Cell Transplantation; Prognosis; Real-Time Polymerase Chain Reaction; RNA, Neoplasm; Survival Analysis; Trans-Activators; Transplantation, Autologous; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine; Young Adult | 2013 |
[Analysis on clinical response of IA and DA regimens in the treatment of 74 newly diagnosed acute myeloid leukemia patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2013 |
Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Young Adult | 2013 |
Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Topics: 5'-Nucleotidase; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine Kinase; DNA Methylation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Inactivation, Metabolic; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Nucleophosmin; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Survival Analysis; Tandem Repeat Sequences; Topoisomerase I Inhibitors; Young Adult | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.
Topics: Aged; Aged, 80 and over; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Risk; Severity of Illness Index; Treatment Outcome | 2013 |
Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prevalence; Prognosis; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Dexamethasone; Erythroid Cells; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Megakaryocytes; Mitoxantrone; Neoplasms, Second Primary; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vincristine | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anthracyclines; Antibiotics, Antineoplastic; Biotransformation; Carcinoma; Cell Line, Tumor; Cell Survival; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Induction; Enzyme Inhibitors; Flavanones; Humans; Hydroxyprostaglandin Dehydrogenases; Idarubicin; Kinetics; Neoplasm Proteins; Oxidation-Reduction; Recombinant Proteins | 2014 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Daunorubicin; Disease-Free Survival; DNA, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Hemoglobins; Humans; Idarubicin; Kaplan-Meier Estimate; Latin America; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Tandem Repeat Sequences; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
A "body armor" of leukemia cutis.
Topics: Adult; Antineoplastic Agents; Cell Movement; Daunorubicin; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Sarcoma, Myeloid; Skin; Skin Neoplasms; Transplantation, Homologous | 2015 |
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Treatment Outcome | 2016 |
Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Case-Control Studies; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Endostatins; Female; Fibroblast Growth Factors; Gene Expression; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; ROC Curve; Treatment Outcome | 2015 |
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Genome, Human; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mutation; Outcome Assessment, Health Care; Polymorphism, Genetic; Prognosis; Recurrence; RNA, Messenger; Sequence Analysis, RNA | 2015 |
Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Bilirubin; Breast Neoplasms; Daunorubicin; Doxorubicin; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Middle Aged; Oxidative Stress; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left | 2015 |
Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2015 |
The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; China; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Gene Frequency; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-kit; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Topics: Cytarabine; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Guideline Adherence; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Practice Guidelines as Topic | 2016 |
Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cytarabine; Daunorubicin; Echinocandins; Febrile Neutropenia; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipopeptides; Male; Micafungin; Middle Aged; Mycoses; Prospective Studies; Young Adult | 2016 |
The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies | 2016 |
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Safety; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Thioguanine; Tumor Suppressor Protein p53 | 2017 |
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; DNA Damage; DNA Repair; Drug Therapy; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Young Adult | 2017 |
[Complete Remission Rate and Adverse Ractions of Three Different Chemotherapy Regimens in the Treatment of Adult Patients with Newly Diagnosed Non-M3 AML].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2018 |
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; United Kingdom; Vidarabine; Young Adult | 2018 |
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine | 2019 |
Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Time Factors | 2019 |
Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Russia; Survival Rate; Young Adult | 2018 |
COMMON STEM. -rubicin.
Topics: Anthracyclines; Daunorubicin; Doxorubicin; Epirubicin; Humans; Idarubicin; Terminology as Topic | 2016 |
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; Disease-Free Survival; DNA Methylation; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Time Factors | 2019 |
The influence of charge and lipophilicity of daunorubicin and idarubicin on their penetration of model biological membranes - Langmuir monolayer and electrochemical studies.
Topics: Antineoplastic Agents; Cell Membrane; Daunorubicin; Dimyristoylphosphatidylcholine; Hydrophobic and Hydrophilic Interactions; Idarubicin; Static Electricity; Unilamellar Liposomes | 2020 |
Pathological changes of the myocardium in reworsening of anthracycline-induced cardiomyopathy after explant of a left ventricular assist device.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiotoxicity; Daunorubicin; Device Removal; Disease Progression; Female; Fibrosis; Heart-Assist Devices; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Myocardium; Time Factors; Ventricular Function, Left | 2020 |
Single-molecule brightness analysis for the determination of anticancer drug interactions with DNA.
Topics: Antibiotics, Antineoplastic; Daunorubicin; DNA; Doxorubicin; Drug Interactions; Idarubicin | 2020 |
Sensitive Analysis of Idarubicin in Human Urine and Plasma by Liquid Chromatography with Fluorescence Detection: An Application in Drug Monitoring.
Topics: Antibiotics, Antineoplastic; Chromatography, Liquid; Daunorubicin; Drug Monitoring; Fluorescence; Humans; Idarubicin; Limit of Detection; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction | 2020 |
Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2022 |
Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Cohort Studies; Daunorubicin; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Prospective Studies; Tretinoin | 2022 |
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2023 |